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Abstract 
Background and Objectives 
Pituitary adenomas are the most common tumors of the sella turcica. 
Incidental small pituitary adenomas are very common and seen in up to one-
fifth of magnetic resonance imaging (MRI) studies. Treatment is based on 
clinical or biochemical indications. Many pituitary tumors can be left for 
follow-up, and some adenomas can be controlled with medication. 
Transsphenoidal surgery is indicated for specific functional and nonfunctional 
pituitary adenomas. Surgical techniques, hormonal medication, and 
radiotherapy are constantly evolving. Subsequently, improved tumor control 
and hormonal balance, contributing to a normal health-related quality of life 
(HRQoL) may be observed. Our objectives here were to describe the 
transitional phase from microscopic to endoscopic surgery for nonfunctional 
pituitary adenomas (NFPAs), and to outline the HRQoL and its determinants 
after treatment of different pituitary adenomas in a recent cohort from a single 
pituitary center. 
Materials and Methods 
We retrospectively collected the relevant data for a total of 320 patients who 
had undergone primary surgery for a newly diagnosed pituitary adenoma 
during 2000-2010 at Helsinki University Hospital. The first part of our study 
included 185 consecutive patients who had transsphenoidal surgery for NFPA. 
These patients were divided into two groups based on the surgical approach: 
microscopic (n=144) and endoscopic (n=41). Tumor size, location, and 
cavernous sinus invasion, prevalence of anterior hypopituitarism and diabetes 
insipidus, visual function, complication rates, and surgical time were 
compared between the groups. The second part of our study used a cross-
sectional design and comprised all pituitary adenoma types. Each patient alive 
was sent a questionnaire (the 15D) assessing the HRQoL at the beginning of 
2013, a mean of 7.4 years after the primary transsphenoidal surgery. One 
hundred functional pituitary adenoma (FPA) and 137 NFPA patients 
responded (response rate 78% and 74%, respectively). We then compared 
HRQoL (15D scores) between patients and a large sample of an age- and 
gender-standardized Finnish general population. Independent factors 
 
 
 
 
influencing the overall HRQoL (mean 15D score) were estimated using 
multivariate analysis. 
Results 
The effect of NFPA surgery on pituitary function in both surgical groups 
(microscopic and endoscopic) was neutral as evaluated at the 3-month follow-
up; hypopituitarism had improved in 7% and 9% and had worsened in 13% 
and 9%, respectively. Of the patients, 51% in both groups received 
replacement therapy. Total tumor removal based on the 3-month follow-up 
MRI was achieved in 45% and 56% of patients, respectively (p=0.14). Visual 
fields had normalized or improved in 90% and 88% of patients, respectively 
(p=0.79). Postoperative cerebrospinal fluid leak appeared in 4% and 2% 
(p=0.74), and diabetes insipidus (transient or permanent) in 8% and 5% 
(p=0.54) of cases, respectively. Larger tumor size (p< 0.0005) and endoscopic 
technique (p=0.03) were independent predictors of increased mean surgical 
time. 
At the time of survey (mean 7.4 years after transsphenoidal surgery), 44% 
and 62% of the FPA and NFPA patients, respectively, received replacement 
therapy. Hormonal remission rate of FPAs was 91%. Mean 15D scores were 
similar in FPA patients and their controls (0.917 vs. 0.922, p=0.568) and near-
normal in NFPA patients compared with their controls (0.885 vs. 0.903, 
p=0.07). 
On single dimensions, FPA patients were worse off regarding speech and 
sexual activity (both p<0.05), and NFPA patients had impaired dimensions of 
vision and sexual activity (both p<0.0005), more depression and distress 
(p=0.005 and 0.009, respectively), and less discomfort and symptoms 
(p=0.19). 
Older age, thyroxine substitution and comorbidities were associated with 
impaired mean 15D score in both FPA and NFPA patients. Cushing’s disease 
independently predicted compromised mean 15D score. Re-operation and 
higher body mass index were independent predictors of impaired HRQoL and 
hydrocortisone and testosterone (males only) substitutions of improved 
HRQoL in NFPA patients. Radiotherapy had no effect on mean 15D score. 
Conclusions 
A good short-term surgical outcome can be achieved during the initial phase of 
transition from microscopic to endoscopic transsphenoidal surgery for NFPA 
 
 
 
 
patients. Our first endoscopic single-center consecutive case series showed a 
trend towards improved tumor control but the operative time was longer than 
with the microscopic technique. 
Current multimodal treatment protocols with optimized hormonal 
replacement therapies enable normal or at least near-normal overall HRQoL to 
be achieved in the majority of patients with all types of pituitary adenomas. 
However, patients with Cushing’s disease and NFPA may have clinically and 
statistically significant impairments of some single dimensions compared with 
the general population. Comorbidities are strong determinants of compromised 
overall HRQoL in patients treated for pituitary adenomas. 
 
 
 
 
Tiivistelmä 
Tausta ja tarkoitus 
Aivolisäkeadenooma on tavallisin sellassa eli kallonpohjan turkinsatulassa 
esiintyvä kasvain. Mahdollisen hormonaalisen aktiivisuuden (erityksen) 
perusteella aivolisäkeadenoomat jaetaan toimimattomiin ja toimiviin. 
Prolaktinooma on yleisin toimiva adenooma ja hoidetaan yleensä lääkityksellä. 
Kasvuhormonin liikaerityksestä johtuva akromegalia ja kortikotropiinin 
(ACTH) liikaerityksestä johtuva Cushingin tauti ovat seuraavaksi yleisimmät. 
Pieniä toimimattomia aivolisäkkeen kasvaimia todetaan sattumalöydöksinä 
jopa viidenneksessä pään magneetti kuvauksista (MK). Aivolisäkeadenoomat 
jaetaan koon perusteella mikro- (läpimitta <10 mm) ja makroadenoomiin 
(läpimitta ≥10 mm). Oireettoman aivolisäkeadenooman (esim. toimimaton 
mikroadenooma) hoidoksi riittää tavallisesti seuranta. Hoitoaiheet perustuvat 
kliinisiin ja biokemiallisiin löydöksiin. Tietyt  aivolisäkeadenoomat poistetaan 
transsfenoidaalista reittiä tehtävällä leikkauksella. Osa biokemiallisesti 
aktiivisista kasvaimista hoidetaan lääkityksellä. Toimivat aivolisäkeadenoomat 
hoidetaan aina. Makroadenooma, joka painaa näköhermo(j)a heikentäen 
näkökykyä vaatii nopeata kirurgista hoitoa. Makroadenoomat voivat myös 
heikentää aivolisäkkeen normaalia toimintaa ja aiheuttaa hypopituitarismin. 
Kaikki aivolisäkehormoniakselit tutkitaan erikseen ja etenkin 
hypokortisolismin korvaushoidon aloitus on tärkeää.  
Kirurgiset tekniikat, lääkehoito ja sädehoito ovat jatkuvasti kehittyneet. Siksi 
aivolisäkeadenoomien hoidon tulosten ja sen myötä myös elämänlaadun 
voidaan olettaa parantuneen.  Tämän tutkimuksen tarkoituksena oli kuvailla 
siirtymävaihetta mikroskooppisesta leikkaustekniikasta endoskooppiseen 
tekniikkaan toimimattomien aivolisäkeadenoomien hoidossa. Lisäksi 
selvitimme terveyteen liittyvää elämänlaatua ja siihen vaikuttavia tekijöitä eri 
tyyppisten aivolisäkeadenoomien leikkaushoidon jälkeen. 
Aineisto ja menetelmät 
Vuosina 2000-2010 Helsingin yliopistollisessa keskussairaalassa leikattiin 320 
uutta aivolisäkeadenoomapotilasta, joiden sairauskertomustiedot kerättiin 
takautuvasti. Ensimmäisessä osatyössä tutkittiin 185 potilasta, jotka leikattiin 
toimimattoman aivolisäkeadenooman vuoksi transsfenoidaalista reittiä. 
Potilaat jaettiin kahteen ryhmään leikkaustekniikan perusteella: 
 
 
 
 
mikroskooppinen (n=144) ja endoskooppinen (n=41). Kasvaimen kokoa, 
sijaintia ja invaasiota sinus cavernosukseen, aivolisäkkeen vajaatoimintaa, 
näkökykyä, leikkauskomplikaatioita sekä leikkauksen kestoa vertailtiin 
ryhmien välillä. 
Toisessa ja kolmannessa osatyössä selvitettiin läpileikkaustutkimuksella eri 
tyyppisten aivolisäkeadenoomapotilaiden terveyteen liittyvää elämänlaatua 
15D mittarilla. Vuoden 2013 alussa, keskimäärin 7.4 vuotta 
transsfenoidaalisen leikkauksen jälkeen, kaikille elossa oleville potilaille 
lähetettiin elämänlaatua mittaavat kyselylomakkeet. Kyselyyn vastasi 100 
hormonaalisesti toimivan ja 137 toimimattoman aivolisäkeadenooman vuoksi 
leikattua potilasta (vastanneiden osuudet 78% ja 74%). Näiden potilaiden 
elämänlaatua (15D arvoja: profiilipisteet ja kokonaisindeksi) verrattiin suureen 
kaltaistettuun suomalaiseen taustaväestöön. Itsenäisiä elämänlaatua (15D 
indeksi) selittäviä tekijöitä arvioitiin monimuuttuja-analyysilla. 
Tulokset 
Toimimattomien aivolisäkeadenoomien leikkaushoidon vaikutusta arvioitiin 
seurantakäynnin yhteydessä 3 kuukautta leikkauksen jälkeen. Aivolisäkkeen 
toiminnan muutokset olivat molemmissa ryhmissä (mikroskooppinen ja 
endoskooppinen) neutraaleja: hypopituitarismi oli korjaantunut 7%:lla ja 
9%:lla ja pahentunut 13%:lla ja 9%:lla vastaavissa ryhmissä. Molempien 
ryhmien potilaista 51% tarvitsi korvaushoitoa. MK:n perusteella kasvain 
todettiin kokonaan poistetuksi 45%:lla ja 56%:lla (p=0.14). Näkökentät 
normalisoituivat tai paranivat 90%:lla ja 88%:lla (p=0.79). Leikkauksen 
jälkeistä likvorvuotoa todettiin 4%:lla ja 2%:lla (p=0.74) ja diabetes insipidus 
(ohimenevä tai pysyvä) 8%:lla ja 5%:lla (p=0.54). Kasvaimen suurempi koko 
(p<0.0005) ja endoskooppinen tekniikka (p=0.03) ennustivat pidempää 
leikkauksen kestoa. 
Kyselytutkimuksen ajankohtana (keskimäärin 7.4 vuotta leikkauksen jälkeen) 
44% toimivan ja 62% toimimattoman aivolisäkeadenooman vuoksi leikatuista 
potilaista tarvitsi hormonikorvaushoitoa. Toimivista adenoomista 91% oli 
hormonaalisessa remissiossa. Keskimääräiset 15D indeksit olivat 
samankaltaiset toimivan adenooman vuoksi leikatuilla potilailla ja 
taustaväestöllä (0.917 ja 0.922, p=0.568), ja lähes normaalit toimimattomien 
adenoomien ryhmässä taustaväestöön nähden (0.885 ja 0.903, p=0.07). 
 
 
 
 
Merkittävimmät heikentyneet elämänlaadun ulottuvuudet toimivien 
adenoomien ryhmässä olivat puhuminen ja seksuaalisuus (molemmissa 
p<0.05), ja toimimattomien adenoomien ryhmässä näkökyky ja seksuaalisuus 
(molemmissa p<0.0005) sekä masennus ja ahdistuneisuus (p=0.005 ja 0.009). 
Korkeampi ikä, tyroksiini korvaushoito ja oheissairaudet ennustivat 
heikompaa 15D indeksiä molemmissa ryhmissä (toimivat ja toimimattomat). 
Toimivien adenoomien ryhmässä Cushingin tauti ennusti huonompaa 15D 
indeksiä. Toimimattomien adenoomien ryhmässä uusintaleikkaus ja 
korkeampi painoindeksi (BMI) olivat 15D indeksiä heikentäviä, mutta 
hydrokortisoni- sekä (miesten) testosteroni korvaushoito 15D indeksiä 
parantavia ennustetekijöitä. Stereotaktisella sädehoidolla ei ollut vaikutusta 
15D indeksiin kummassakaan ryhmässä. 
Johtopäätökset 
Toimimattomien aivolisäkekasvainten hyvät leikkaustulokset voitiin säilyttää 
mikroskooppisesta endoskooppiseen leikkaustekniikkaan tapahtuvan 
siirtymävaiheen aikana. Endoskooppisesti leikattujen potilaiden ryhmässä oli 
suuntaus vähäisempään jäännöskasvaimen määrään, mutta leikkausaika oli 
pidempi verrattuna mikroskooppisesti leikattuun ryhmään. 
Nykymenetelmin leikatuilla ja hoidetuilla aivolisäkeadenoomapotilailla 
todettiin lähes normaali elämänlaatu (15D indeksi). Cushingin tauti ja 
toimimattomat aivolisäkeadenoomat kuitenkin heikensivät joitakin yksittäisiä 
elämänlaadun ulottuvuuksia taustaväestöön verrattuna. Lisäksi 
oheissairauksien kertyminen oli merkittävä elämänlaatua (15D indeksi) 
heikentävä itsenäinen tekijä aivolisäkeadenoomapotilailla. 
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AcroQoL  Acromegaly Quality of Life Questionnaire 
ACTH  Adrenocorticotropic hormone 
ADH  Antidiuretic hormone 
AIP  Aryl hydrocarbon receptor-interacting protein 
ANOVA  Analysis of variance  
BMI  Body mass index 
CBTRUS  Central Brain Tumor Registry of the United States 
CD  Cushing’s disease 
CI  Confidence interval 
CIS  Checklist individual strength questionnaire 
CRH  Corticotropin-releasing hormone 
CRT  Craniotomy 
CS  Cavernous sinus 
CSF  Cerebrospinal fluid 
CT  Computerized tomography 
Cushing QoL Cushing Quality of Life Questionnaire 
DI  Diabetes insipidus 
EuroQoL (EQ-5D) European Quality of Life Scale 
FIPA  Familial isolated pituitary adenoma 
FPA  Functional pituitary adenoma 
FSH  Follicle-stimulating hormone 
GH  Growth hormone 
GHQ-12/28/30 General Health Questionnaire-12/28/30 
GHRH  Growth hormone-releasing hormone 
GWBS  General Well-Being Schedule 
HADS  Hospital Anxiety and Depression Scale 
HRQoL  Health-related quality of life 
HUH  Helsinki University Hospital 
HUSLAB Laboratory of Helsinki University Hospital 
IGF-1  Insulin-like growth factor 1 
IPSS  Inferior petrosal sinus sampling 
LH  Luteinizing hormone 
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MEN  Multiple endocrine neoplasia 
MIB-1  Monoclonal antibody MIB-1 
MRI  Magnetic resonance imaging 
NFPA  Nonfunctional pituitary adenoma 
NHP  Nottingham Health Profile 
NS  Nonsignificant 
MDI  Major Depression Inventory 
MFI  Multi Fatigue Index 
OGTT  Oral glucose tolerance test 
PA  Pituitary adenoma 
(P)GWBS                      (Psychological) General Well-Being Schedule 
PRL                               Prolactin 
p53                                Tumor suppressor p53 
QALY                           Quality-adjusted life-years 
RT                                 Radiotherapy 
SD  Standard deviation 
SE  Spin echo 
SF-20/36/SF-6D Short-Form health survey 
SIR  Standardized incidence ratio 
SIADH                     Syndrome of inappropriate secretion of antidiuretic 
hormone 
SSA  Somatostatin analog 
STR  Stereotactic radiotherapy 
TSH  Thyroid-stimulating hormone 
TSS  Transsphenoidal surgery 
Tuebingen CD-25 Tuebingen Cushing’s disease quality of life 
inventory 
WHO  World Health Organization 
WHODASII WHO Disability Assessment Schedule 
15D  15D questionnaire 
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A. Introduction 
Pituitary adenomas (PAs) are common benign intracranial tumors. According 
to autopsy and magnetic resonance imaging (MRI) studies, their overall 
estimated prevalence is 17% (range 1.5%-39%) [1]. The biological and clinical 
manifestation of PAs is wide, from small, incidental, asymptomatic lesions to 
giant, invasive, hormone-producing tumors [2]. The objectives of treatment 
depend on the biochemical and anatomical characteristics of the tumor, but 
generally include preservation/restoration of pituitary function, decompression 
of neural structures and prevention of tumor recurrence. Treatment modalities 
have been constantly evolving, with introduction of new medications for 
biochemical control of tumors [3, 4], improved optimization of hormonal 
replacement therapies [5], novel surgical techniques for more efficient tumor 
removal [6, 7] and targeted methods to deliver radiotherapy [8]. 
The endoscopic transsphenoidal approach offers some technical advantages 
over the traditional microscopic approach, but the superiority of one technique 
over the other in terms of treatment outcome has not been established [9-11]. 
The trend, however, is strongly towards adopting the endoscopic technique in 
pituitary centers [12]. In Helsinki University Hospital (HUH) the microscope 
was replaced with the endoscope in 2008. 
We conducted this study to elucidate the effects of operative technical 
evolution and multiple modern treatment modalities and to delineate the 
health-related quality of life (HRQoL) after transsphenoidal surgery for PAs in 
HUH between 2000 and 2010. 
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B. Review of the literature 
1. Normal pituitary gland and its function 
 
The pituitary gland is vital for the maintenance of the body’s homeostatic 
functions of metabolism, growth and reproduction. This pea-sized (averaging 
13 x 9 x 6 mm) gland, weighing about 0.5 g, is located at the base of the brain 
in the sella turcica just above the sphenoid sinus. It can be seen as a protrusion 
from the bottom of the hypothalamus to which it is connected with a stalk also 
known as the infundibulum. The pituitary gland consists of anterior and 
posterior lobes containing the adenohypophysis and neurohypophysis, 
respectively. A third, intermediate part between the anterior and posterior 
lobes is not very distinct in humans [13]. 
The neurohypophysis is an extension of the hypothalamus, and is 
composed of neuronal processes. Antidiuretic hormone (ADH) is synthesized 
in the hypothalamus and stored in the neurohypophysis to be released for 
maintenance of the body’s water balance. Oxytocin, another neurohypophyseal 
hormone, plays an important role in sexual reproduction, especially during and 
after labor. Secretion of both neurohypophyseal hormones is under 
hypothalamic control. They are released to the blood circulation through 
pituitary vasculature [14]. 
The adenohypophysis is composed of hormone-secreting 
adenohypophyseal cells, which are of epithelial origin from the oral ectoderm. 
The adenohypophysis contains several cell types specific for different 
adenohypophyseal hormones and their production. Adrenocorticotropin 
(ACTH) stimulates glucocorticoid production of the adrenal cortex. Growth 
hormone (GH) regulates muscle and bone growth in adults. Prolactin (PRL) 
inhibits gonadal function and stimulates breast milk production. Thyroid-
stimulating hormone (TSH), also known as thyrotropin, stimulates the thyroid 
gland to produce thyroid hormones. Gonadotropins (LH and FSH) regulate sex 
hormone production in gonads and germ-cell development. All (except PRL) 
of the adenohypophyseal hormones are under dual regulation: hypothalamic 
hormones and systemic. PRL and GH also have a direct feedback mechanism 
to the hypothalamus [13]. 
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2. Pituitary adenomas 
2.1. Pathobiology and development 
Pituitary adenomas (PAs) are benign neoplasms consisting of 
adenohypophyseal cells. They show a wide range of biological behavior in 
terms of hormone secretion and tumor growth. PAs usually arise in the sella 
turcica and rarely elsewhere in the proximity of the sella [2]. A pseudocapsule 
composed of compressed adenohypophyseal tissue surrounds most PAs [15]. 
PAs are classified as micro- or macroadenomas based on their size (<10 mm 
or ≥10 mm, respectively). Depending on the cell line, they are further 
classified as hormonally active or inactive. Their growth rate is variable, but 
usually slow. The direction of growth is typically upwards into the suprasellar 
space towards the optic chiasm. Some PAs can invade downwards into the 
sphenoid sinus or laterally into the cavernous sinus [2, 16]. 
Most PAs are likely to arise from a genetic event (e.g. inactivation of 
tumor-suppressor gene), which alters cell proliferation or survival. This 
mutation allows the adenohypophyseal cell line to become more responsive to 
hormones or growth factors and ultimately leads to clonal expansion and 
development of PA [17, 18]. 
Some PAs have atypical features on immunohistochemical analysis: 
excessive p53 positivity, high proliferative index (MIB-1 over 3%), and 
increased mitotic activity. These tumors can be classified as atypical PAs, but 
their true clinical behavior has not yet been confirmed [19]. Very rarely, 
pituitary tumors metastasize to distant locations and are then classified as 
carcinomas [2]. 
2.2. Predisposing factors 
Little is known about environmental factors promoting PA tumorigenesis, but 
some genetic factors have been found. Multiple endocrine neoplasia type 1 
(MEN1) syndrome is a rare autosomal-dominant disorder caused by mutation 
in the MEN1 gene. This loss of tumor-suppressor gene is associated with a 
high incidence of PAs in affected patients. However, MEN1 mutations have 
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not been identified in patients with sporadic PA [20]. Other rare genetic 
syndromes predisposing to PAs are Carney complex and MEN4 [21] 
Familial isolated pituitary adenoma (FIPA) is a clinical entity in which 
pituitary adenomas of all types occur in multiple members of a kindred in the 
absence of MEN1 [21]. A mutation in the aryl hydrocarbon receptor-
interacting protein (AIP) gene is associated with some (15%) FIPA families 
[21, 22]. The AIP mutation predisposes patients to larger and treatment-
resistant PAs (mostly somatropinomas) at an earlier age and may also be 
found in sporadic cases without FIPA family history [21-23]. 
2.3. Incidence and prevalence 
 Pituitary adenomas may be found incidentally on MRI and autopsy with a 
mean frequency of 22.5% and 14.4%, respectively [1]. Clinically significant 
PAs are less common, but recent data suggest increased incidences relative to 
earlier reports [24] [25]. 
PAs have constituted 14.7% of histologically verified central nervous 
system tumors in the US tumor registry (CBTRUS 2004-2007). The 
standardized incidence rate per 100000 (SIR) for PAs was 3.13 [26]. An 
Austrian registry-based study reported much lower SIR (1.63) for 
histologically verified PAs [27]. Incidence rates based on tumor specimen may 
underestimate the true incidence, as many PAs are diagnosed on a radiological 
and biochemical basis without histological confirmation. 
In a Swedish population-based survey performed in 1958-1991, the age-
standardized incidence of PA was only 0.6-1.1 cases per 100000 [28]. A more 
recent population-based retrospective study from Northern Finland included 
clinically relevant PA cases based on hormonal and radiological studies in 
1992-2007. The authors identified 355 patients with freshly diagnosed PA and 
reported SIR of 3.98 [29]. Another recent study from Sweden, using the same 
design, reported a very similar SIR (3.9) for 2001-2011 [30]. The most 
common PA subtypes were prolactinoma and NFPA, combined constituting 
86-88% of cases. The higher incidence numbers in cohorts collected after the 
1990s can be explained by the more frequent use of high-resolution MRI as a 
diagnostic tool, resulting in larger numbers of incidental findings. 
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There is a clear rise in PA incidence in older males. This increase is most 
pronounced in NFPAs, while other subtypes occur at more stable rates over 
different age groups in males [29, 30].  In females, the PA incidence peaks in 
young adults (25-34 years), gradually decreasing thereafter. The upswing may 
be explained by diagnosis of prolactinomas when females reach the 
reproductive age. 
A vast majority of patients harboring PAs are adults, with only 3-6% of 
cases being under 20 years of age [31]. According to the CBTRUS database, 
the SIR of pituitary tumors in the US before the age of 20 years is 0.49 cases 
per 100000. 
Two population-based studies from Europe (Belgium and UK) explored 
the prevalence of clinically relevant PAs [32, 33], reporting a total prevalence 
of 94.0 and 77.6 per 100000, respectively. This roughly corresponds to one 
case per 1000 population. Both papers suggested that the most common PA 
subtype was prolactinoma, a clear majority of which were microadenomas 
(89%) in female patients (80%). Overall, women harbored PA twice as often 
as men (ratio 2:1) in both studies. 
2.4. Hormonally active pituitary adenomas 
2.4.1. Prolactinomas 
Prolactinomas are the most common hormone-secreting tumors of the pituitary 
gland, representing up to 40% of all pituitary tumors. They present as 
microadenomas in 90% of cases and appear most frequently in females aged 
between 20 and 50 years; the sex ratio is 10:1 [34, 35]. Premenopausal women 
typically present with amenorrhea, infertility, and galactorrhea. Diagnosis is 
based on increased serum prolactin concentrations in the presence of an 
adenoma observed on MRI, after excluding other causes of raised prolactin 
levels. Some patients (typically males) may present with visual disturbance 
and hypopituitarism as a result of mass effect caused by macroprolactinoma. 
For asymptomatic microadenomas, follow-up may be sufficient (typically 
postmenopausal women). The first-line treatment of symptomatic 
prolactinoma is dopamine agonist - cabergoline is preferred over 
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bromocriptine and quinagolide - which often reverses hyperprolactinemia 
relatively quickly and relieves eventual symptoms related to mass effect 
(headache, visual symptoms) often within a few days. After established 
normalization of prolactin concentrations and near complete tumor 
disappearance, the medication may be discontinued. Some patients will stay in 
remission [34, 36]. 
If dopamine agonist treatment is ineffective (10-20%) or the patient is non-
compliant and/or suffers from side-effects (nausea, vomiting, dizziness), 
surgery maybe indicated. Over 70% of patients operated on for 
microprolactinoma reach hormonal remission [34, 36]. Macroprolactinomas 
often have an invasive growth pattern and are therefore more difficult to cure 
surgically, with remission rates under 40% [34, 36]. Recurrences after initial 
surgical remission are reported between 0 and 50% of prolactinoma cases, 
reflecting differences in neurosurgical expertise and patient selection between 
centers [36]. Radiotherapy has a minor role since medication and/or surgery 
very often have sufficient efficacy in treatment of prolactinomas. 
2.4.2. Growth hormone-producing adenomas 
Excessive production of GH leads to acromegaly, which markedly shortens 
life expectancy if left untreated or poorly controlled [37, 38]. Acromegaly 
typically presents as an insidious progressive disease with dysmorphic changes 
(broadened hands and feet, widened nose, and prominent cheekbones and 
jaw). Other manifestations are cardiovascular (arterial hypertension, 
cardiomyopathy, valve disease), metabolic (diabetes), sleep apnea, 
arthropathies, and increased risk for colon cancer [37]. In pediatric patients, 
excessive GH production leads to gigantism. 
The diagnosis is based on typical clinical symptoms and biochemically 
confirmed increased GH concentration, which is not suppressed following an 
oral glucose load (oral glucose tolerance test, OGTT) [39].  An increase 
(relative to the age-adjusted normal range) in the serum concentration of IGF-
I, the main GH-dependent growth factor, supports the diagnosis. Mixed GH- 
and PRL secreting adenomas are relatively common (25%), with clinical 
behavior similar to acromegaly [37]. 
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Treatment of acromegaly aims to eliminate morbidity and reduce mortality 
to the expected age- and sex-adjusted rates. This is optimally achieved by 
using safe treatments to remove the mass effect of the tumor and to normalize 
the GH-IGF-1-axis function. Currently, the first-line treatment of GH-
secreting adenoma is surgical removal, ideally with preservation or subsequent 
restoration of pituitary function [40, 41]. Approximately 80% of patients with 
microadenomas and less than 50% of patients with macroadenomas can be 
defined as controlled with transsphenoidal surgery [42, 43]. A small number of 
patients (less than 5%) develop tumor recurrence, although it is relatively rare 
compared with other functioning adenomas [44, 45]. If acromegaly is not 
controlled with surgery alone or surgery is not feasible or contraindicated, 
patients are offered medical treatments. Radiotherapy is recommended as a 
third treatment option in case both surgical and medical treatments fail to 
control the disease [40, 41]. 
Somatostatin receptor ligands (somatostatin analogs, SSAs, i.e. octreotide 
and lantreotide) are the primary medical treatment option for acromegaly, 
although cabergoline might be considered in mild cases [41]. If the response to 
SSA is not adequate, a switch to pegvisomant (GH-receptor antagonist) 
treatment or more often combination therapy with SSA and pegvisomant or 
cabergoline may be considered. Some authors have reported improved surgical 
remission rates with preoperative SSA treatment [46]. 
2.4.3. Adrenocorticotropic hormone-producing adenomas 
Cushing’s syndrome refers to a condition induced by chronic exposure to 
excess glucocorticoid. In clinical practice, an iatrogenic source of 
glucocorticoid surplus (e.g. treatment of inflammatory diseases) is more 
common than endogenous hypercortisolemia. Cushing’s disease is caused by 
an ACTH-producing PA and represents 60-70% of endogenous Cushing’s 
syndromes [47]. Primary adrenocortical tumors and rare ectopic ACTH 
syndromes are other causes for endogenous hypercortisolemias. Patients 
affected by Cushing’s syndrome have high morbidity and mortality, and 
expeditious diagnostics and treatment are thus advisable [47]. 
Diagnosis of Cushing’s disease is based on serial stepwise investigations, 
which may be complex and puzzling [48, 49]. The majority of cases are 
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females presenting with microadenoma. The diagnostic work-up from a 
clinical standpoint comprises symptoms and signs suggestive of 
hypercortisolemia: cushingoid habitus (central obesity, thinned skin, purple 
striae, proximal muscle weakness, etc.), fatigue, arterial hypertension, glucose 
intolerance, menstrual irregularity, acne, and hirsutism. Biochemical 
diagnostics are preceded by exclusion of exogenous glucocorticoid use, and 
followed by screening and confirmation of excess glucocorticoid load using 
dexamethasone suppression test and measurement of 24 h urinary cortisol and 
late-night salivary cortisol. This is followed by determining whether cortisol 
production is ACTH-dependent or not (measurement of ACTH 
concentrations), and finally differentiating between an ectopic ACTH-
producing tumor and a pituitary source (i.e. Cushing’s disease) using 
corticotropin-releasing hormone (CRH) stimulation test [48].  
If hypercortisolemia is ACTH-dependent, but clinical, biochemical, and 
imaging results are discordant, bilateral inferior petrosal sinus sampling of 
ACTH (IPSS) is usually indicated. The ACTH concentration is then compared 
between the inferior petrosal sinus and peripheral samples (IPS:P). A central 
pituitary source for ACTH overproduction can be assumed if the IPS:P ratio is 
over 2:1 in cases where CRH is not used or if the ratio is over 3:1 after 
administration of CRH [48]. IPSS has a high (98-99%) positive predictive 
value, but unfortunately a lower (22-29%) negative predictive value [48, 50, 
51].  
High-quality pituitary MRI with appropriate imaging sequences is 
mandatory for detecting small adenomas and to give the neurosurgeon an 
exact intraoperative roadmap for finding the target [52]. MRI may remain 
equivocal despite repeated and focused scanning. 
The best treatment for Cushing’s disease is transsphenoidal surgery, which 
is highly effective in expert hands [53]. Surgery should be considered also in 
cases of ACTH-dependent Cushing’s disease and noncentralized or technically 
unsuccessful IPSS without evidence of ectopic tumor [51]. Remission rates 
vary between 65% and 98%, and disease relapse is reported in up to 35% of 
cases at long-term follow up after transsphenoidal surgery [54]. 
A special challenge for the pituitary surgeon is an MRI-negative adenoma, 
which requires careful exploration of the whole pituitary gland in order to find 
the tiny microadenoma. If the adenoma is not found despite all efforts, the 
surgeon has to decide whether to proceed with subtotal hypophysectomy or to 
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withdraw and re-evaluate treatment options postoperatively with the whole 
pituitary team [55, 56]. 
Unfortunately, drugs available for Cushing’s disease have poor efficacy, 
and therefore, long-term medical treatment is seldom indicated [53]. 
Ketoconazole, metyrapone, and mitotane have been used to inhibit the adrenal 
synthesis of steroids [47]. A pituitary-targeted medication, pasireotide, has 
been developed, but its high cost and side-effects (e.g. hyperglycemia) limit its 
use [57]. Generally, drugs may be used as an adjunct in cases where surgery 
has been unsuccessful or contraindicated and while waiting for response to 
radiotherapy [53]. Alternatively, bilateral adrenalectomy may be considered 
when rapid resolution of severe hypercortisolemia is preferred in Cushing’s 
disease [58]. 
2.4.4. Thyroid-stimulating hormone-producing adenomas 
Thyroid-stimulating hormone-secreting PA is a very rare cause of 
hyperthyroidism and constitute only 2% of all pituitary tumors [59]. About 
one-third of TSH-secreting adenomas are plurihormonal, secreting also GH, 
PRL, or rarely gonadotropins [2]. They usually present as macroadenomas 
with mass effect on the surrounding structures. Symptoms of hyperthyroidism 
may be mild and obscured by visual disturbances, hypopituitarism, or 
secretion of other hormones (plurihormonal adenomas). Goiter is very 
common, almost a rule, and many patients are misdiagnosed as having primary 
hyperthyroidism.  
Evidence of increased thyroid hormone concentrations in association with 
measurable TSH concentrations is biochemically characteristic of central 
hyperthyroidism. Dynamic testing (thyroid hormone suppression test), which 
is rarely required, differentiates TSH-secreting PAs from the syndromes of 
thyroid hormone resistance [59, 60]. 
The treatment of choice for TSH-secreting adenomas is transsphenoidal 
surgery [60]. These adenomas are often macroadenomas with a hard 
consistency and invasive growth to parasellar structures, and consequently, 
hormonal remission is achieved in only in 44-58% of cases with surgery alone 
[61, 62]. Medical treatment of TSH adenomas is based on administration of 
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long-lasting somatostatin analogues, which are effective in up to 95% of 
patients [63]. 
2.5. Hormonally inactive adenomas 
Nonfunctional PAs refers to a clinical entity in which symptoms and signs of 
hormonal hypersecretion are absent in the presence of a pituitary tumor. 
Subclasses of NFPAs are null cell adenoma and oncocytoma, which have 
negative hormonal immunostaining [64]. Occasionally, NFPAs present as 
silent adenomas, which express hormones in immunohistochemistry, but do 
not secrete them [2]. 
NFPA is the most common indication for pituitary surgery, constituting 
about 50% of operated PAs [65]. Mean age at diagnosis is between 50 and 55 
years, with slight male preponderance (57%). NFPA typically presents with 
visual disturbance and/or hypopituitarism related to mass effect of the tumor. 
Half of the patients have visual deficits on formal neuro-ophthalmological 
examination and almost 80% have dysfunction of at least one hormonal axis 
on endocrinological assessment [64]. Since NFPA may go unnoticed for years 
(even a lifetime) before reaching a symptomatic size, up to 26% of cases are 
nowadays discovered incidentally on MRI [66]. Occasionally (5-10% of 
cases), hemorrhagic infarction of the adenoma (apoplexy) may cause a sudden 
increase in size and pressure of the tumor and subsequently lead to acute 
severe headache, visual disturbance, and hypopituitarism [64, 67]. However, 
any PA subtype may present with apoplexy. 
Many NFPAs cause mild to moderate hyperprolactinemia by compressing 
the stalk and inhibiting effects of dopamine on lactotroph cells of 
adenohypophysis (stalk effect). In clinical practice, NFPAs can usually be 
distinguished from prolactinomas, which typically produce much higher levels 
of prolactin with respect to smaller tumor size. 
For asymptomatic and small NFPAs, follow-up is usually sufficient. 
Transsphenoidal surgery is the primary treatment for NFPAs. The most 
important objective for surgery is reversal of visual deterioration. At the time 
of surgery, all tumors are macroadenomas, some even giant, making it a 
challenge for the pituitary surgeon to achieve total excision of the lesion. 
Reported rates of gross total resection have ranged from 28% to 83% [64]. 
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However, tumor control seems to be improving since recent papers have 
reported complete resections ranging from 56% to 96% [68]. Despite some 
tumor residuals, the great majority (80%) of patients experience improvements 
in their visual disturbance, with full normalization in up to 40% [64]. Most 
studies report postoperative improvements in hypopituitarism. Recurrences 
after gross total resection are seen on average in 17% (range 0-32%) of cases, 
and residual tumors progress on average in 43% (range 13-73%) of cases 
depending on the length of postoperative follow-up (mean range 4-10 years) 
[64]. NFPAs require extended follow-up of possible hypopituitarism and 
hormonal substitution, and MRI surveillance should be considered on an 
individual basis, guided by the possible residue and its estimated growth [69, 
70]. 
Since medical treatment (e.g. dopamine agonists) is inadequate for 
controlling NFPAs, tumor residuals are, when needed, either re-operated or 
referred for stereotactic radiotherapy [64]. Treatment decisions are made 
individually, favoring watchful waiting in cases where the tumor residual is 
small, asymptomatic, or shows no progression and is situated far away from 
the optic chiasm [71]. Commonly, radiotherapy stops the tumor growth, but 
risks the residual function of the pituitary. Modern stereotactic methods of 
delivering radiotherapy have reduced but not eliminated the harmful effects of 
ionized radiation [72]. 
3. General principles of evaluation 
Clinical and biochemical assessment of pituitary hormonal function is the 
cornerstone of evaluating a possible PA. Assessment of visual function by 
ophthalmological studies and outlining sellar anatomy with radiological 
studies complete the evaluation. Since diagnostic and treatment guidelines are 
different for each PA subgroup, an endocrinologist should carefully oversee 
the stepwise investigations. 
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3.1. Pituitary function 
Excess hormonal production and subsequent symptoms and signs are specific 
for each functional adenoma as already described. The first-line biochemical 
tests of hormonal overproduction are selected accordingly and often repeated 
or supplemented to reach diagnosis. Even if the patient presents with 
neurological symptoms of mass effect with no obvious signs of hormonal 
overproduction, the possibility of a FPA, especially a prolactinoma, should not 
be overlooked. 
Hypopituitarism is defined as a partial or complete defect in anterior (or 
posterior) pituitary hormone secretion. It can be secondary to compression of 
the pituitary gland by the adenoma itself or may develop as a consequence of 
surgery and/or radiotherapy. In addition, hyperprolactinemia may lead to 
hypogonadism. The most commonly hypofunctional anterior pituitary axes are 
adrenal, gonadal, and thyroid. Depending on the degree and number of 
deficient hormones, the presenting symptoms of hypopituitarism can vary 
widely, from subtle hypothyroidism to severe hypocortisolism, which may 
result in shock. ADH deficiency leads to the syndrome of diabetes insipidus 
(DI), inability to concentrate the urine, leading to polyuria, dehydration, and 
extreme thirst and polydipsia, as well as hypernatremia. 
Symptoms and signs secondary to hypopituitarism are reviewed by means of 
clinical examination and careful history. Each anterior hormonal axis is tested 
in patients undergoing diagnostic evaluation for PA [5]. Screening is done by 
measuring basal concentrations of serum cortisol, T4, and in males, 
testosterone, and in females of reproductive age, also by assessing the 
menstrual cycle. Mild forms of hypopituitarism may require stimulation 
testing for proper assessment (e.g. ACTH stimulation for detection of 
hypocortisolism). Generally, all deficient hormones are replaced. 
3.3. Neuro-ophthalmology 
Visual disturbances are noted when the PA grows superiorly beyond the sella 
and compresses optic nerves anteriorly, the optic chiasm centrally, or optic 
tracts posteriorly. The classic presentation is a slowly progressive bitemporal 
hemianopia caused by pressure on nasal fibers of the chiasm. Bilateral 
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deterioration of central visual acuity is a relatively insensitive indicator of 
mass effect and correlates poorly with visual deficit. However, reduced color 
vision is usually one of the first signs of compressive optic neuropathy [73]. 
Neuro-ophthalmological assessment is requested in case of visual 
symptoms or macroadenoma compressing the optic nerve(s) or chiasm. 
Evaluation includes testing of visual fields and acuity, and auxiliary testing 
may be helpful in detecting subtle deficits [74]. 
An abrupt hemorrhage or infarction or both within the pituitary adenoma 
causes pituitary apoplexy, which usually presents with sudden onset of severe 
headache and visual disturbance. Besides visual loss, ophthalmologic 
symptoms often include diplopia due to lateral compression of cranial nerves 
in the cavernous sinus. Unstable or progressive visual deterioration is an 
indication for urgent transsphenoidal decompression and tumor removal [67]. 
3.4. Imaging 
Imaging documents the existence of the pituitary lesion, shows its exact 
location within the gland, and evaluates its size. Imaging does not, however, 
distinguish one type of adenoma from another. It provides anatomical 
information about surrounding structures and their involvement. MRI offers 
soft tissue differentiation, whereas computerized tomography (CT) scanning 
yields information on the bony structures of paranasal sinuses and the skull 
base around the sella [75]. 
The most common MRI technique is a T1-weighted spin echo (SE) 
sequence obtained in coronal and sagittal planes before and after injection of 
intravenous contrast media [75]. The post-contrast sequences are the most 
valuable part of the examination, usually depicting the adenoma as a 
hypoenhancing lesion surrounded an enhancing normal gland. A very useful 
sign, supporting the pituitary origin of the tumor, is the demonstration of a 
connection with the pituitary gland within the sella. 
Additional T2-weighted images are usually obtained in coronal and sagittal 
planes to better outline cystic or calcified areas of the tumor. For 
neurosurgeons, MRI is invaluable for planning pituitary transsphenoidal 
surgery. Preoperatively, tumor extensions to supra- and parasellar structures 
must be carefully reviewed. Position and possible deviation of the pituitary 
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stalk provides clues as to where the adenohypophysis is displaced in cases of 
large macroadenomas. The degree of tumor compression on the optic chiasm 
is often crucial information regarding the operative indication, especially in 
NFPAs. Involvement of cerebral arteries and invasion of the cavernous sinus 
(CS) are critical points in defining the surgical objective. To better assess CS 
involvement preoperatively, Knosp et al. have proposed a classification in five 
degrees [76]. This is based on coronal sections of unenhanced and enhanced 
MR imaging, with the internal carotid artery serving as the radiological 
landmark (Figure 1). The critical area where the invasion of the CS space 
becomes very likely is between the midcarotid line and the lateral side of the 
carotid arteries, which represents Grade 2. An increasing degree of CS 
invasion complicates or even prevents total tumor resection. 
 
 
Figure 1. Knosp classification system used for assessing invasiveness of pituitary 
adenomas. The dashed reference lines (medial side, midpoint, and lateral side of the 
internal carotid artery) indicate the maximum lateral extension for each grade. The 
figure is modified from Di Leva et al.[78] 
 
The sensitivity of routine T1-weighted SE sequences is usually sufficient 
for detecting macroadenomas. However, tiny microadenomas may require 
special sequences to be visible on MRI. This is relevant especially in 
Cushing’s disease, in which a negative MRI is not uncommon [52]. The 
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contrast between the hypoenhancing microadenoma and the hyperenhancing 
surrounding pituitary gland can be improved by using either a spoiled gradient 
recall acquisition technique or dynamic fast SE sequences with 1.5 mm slice 
thickness [75]. Three Tesla MRI may offer further improved resolution as 
compared with 1.5 Tesla scanners [77]. Regardless of the chosen method, 
imaging should start immediately after the contrast media injection because a 
delay will diminish the deferential enhancement of the adenoma from the 
normal pituitary. 
4. Surgical treatment of pituitary adenomas 
4.1. History and evolution of transsphenoidal surgery 
The first published attempt to reach a pituitary tumor was made in year 1893 
[79].  A temporal approach was used for a 35-year-old woman presenting with 
signs and symptoms consistent with intracranial hypertension and acromegaly. 
Intraoperative swelling of the brain prevented tumor resection, but 
decompressive craniectomy relieved symptoms, and the patient survived for 
two months. Autopsy revealed a pituitary mass the size of “a tangerine 
orange” with extensive parasellar invasion. Subsequently, Sir Victor Horsley 
operated on ten pituitary tumors during 1904-1906 using subfrontal and 
temporal approaches, with a 20% mortality rate [80]. At the same time (1905), 
German neurosurgeon Feodor Krause used a frontal transcranial approach to 
reach the sella turcica. His procedure provided the basis for later modifications 
introduced by Dandy, Frazier, and Cushing. 
High mortality rates of early transcranial approaches led surgeons to seek 
alternative and safer routes to the sella turcica. In 1907, a successful removal 
of the pituitary through a lateral rhinotomy was reported [81]. During the next 
three years the transsphenoidal approach was further improved by introducing 
endonasal transseptal and sublabial techniques (Hirsch and Halstead, 
respectively) [80]. Harvey Cushing quickly adapted the transsphenoidal 
technique by using a sublabial incision, and introduced submucosal dissection 
and resection of the nasal septum, and endotracheal (instead of local) 
anesthesia. Cushing subsequently used the transsphenoidal approach for over 
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200 patients between the years 1910 and 1929. By the end of the 1930s, he 
nearly abandoned the transsphenoidal technique and continued using the 
transfrontal approach, which he had learned to perform outstandingly [82]. 
The neurosurgical community followed Cushing’s example, and the 
transsphenoidal technique was virtually forgotten for the next 35 years. 
Norman Dott had visited Cushing during 1923-1924 and adopted the 
transsphenoidal technique, which he kept using contrary to the neurosurgical 
the mainstream after his return to Edinburgh. A young French neurosurgeon, 
Gerard Guiot, adopted the procedure from Dott while at the Edinburgh Royal 
Infirmary in 1956. Back in Paris, Guiot refined the transsphenoidal approach 
by using fluoroscopy to navigate his instruments during the nasal and sellar 
phases of the operation [83]. He applied the transsphenoidal technique in more 
than 1000 PAs and pioneered its use for craniopharyngiomas, clival 
chordomas, and parasellar lesions as well. 
Jules Hardy of Montreal, Canada, worked as a fellow to Guiot in Paris to 
learn his transsphenoidal approach. By 1968, Hardy had refined the technique 
further and had introduced the operating microscope and the concept of using 
it for selective adenoma removal while preserving pituitary function [84]. The 
microsurgical approach revolutionized the transsphenoidal technique, which 
was gradually adopted as the first-line choice for PA removal worldwide. 
Besides improved illumination with the microscope, the increasing availability 
of antibiotics and the introduction of corticosteroid replacement led to 
decreased postoperative morbidity and mortality. Three decades earlier, 
Cushing had been missing these three factors, and this most likely caused him 
to revert to the transcranial approach. 
Since Hardy launched the new era of transsphenoidal microsurgery, it has 
undergone several refinements. It is the preferred operative technique for PA 
removal today [85, 86], and it currently has two main variations: microscopic 
and endoscopic. 
The first evolutionary steps of the endoscopic technique were described by 
Guiot already in 1963 [87]. However, it took another 30 years of technical 
development before the endoscopic equipment offered high-quality 
visualization of the operative field, which allowed accurate microsurgical 
dissection [88, 89]. Extended approaches have been described, and the 
introduction of a fully endoscopic endonasal technique has further expanded 
the indications and limits of transsphenoidal surgery [90, 91]. Currently, most 
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centers use the endoscopic technique, and the continuous need for better 
results will push the techniques and skills to new levels in the future [12, 92]. 
Transnasal pituitary surgery was first introduced in Finland by 
otorhinolaryngologist Bertel Grahne. He was followed by neurosurgeon Simo 
Valtonen, who used the sublabial transsphenoidal approach, which he had 
learned from Graham Teasdale while visiting the Glasgow Institute of 
Neurological Sciences during 1976-1977. After returning to Helsinki, Dr. 
Valtonen gradually took over transsphenoidal pituitary surgery and gained 
further experience by visiting Dr. Gerard Guiot in Hôpital Foch, Paris. After a 
few years as the sole pituitary surgeon in Helsinki, Dr. Valtonen was joined by 
his neurosurgical colleague Antti Poranen who introduced the transseptal 
technique during the early 1980’s. The microscopic transsphenoidal technique 
was the method of choice until June 2008, when it was replaced by the 
endoscopic approach. 
4.2. Transsphenoidal approaches 
4.2.1. Microscopic technique 
The microscopic technique is well described by several authors [90, 93, 
94]. Using the keywords “microscopic transsphenoidal surgery” retrieves 
approximately 200 illustrative operative videos from YouTube (September 
2015). The microscopic technique has three variations for access to the 
sphenoid sinus: sublabial [94], transseptal (submucosal endonasal) [93], and 
direct endonasal [90] techniques. Sublabial access through gingival incision 
offers the widest route and view to the sphenoid sinus and sellar floor. By 
contrast, direct endonasal modification is the least invasive as minimal 
dissection of the anterior nasal structures is required. The transseptal technique 
involves an anterior septal incision for access and a subsequent submucosal 
septal dissection. To keep the surgical pathway open, an automatic retractor of 
appropriate size is routinely introduced, if necessary, under fluoroscopic 
control. The sphenoid articulation of the vomer is removed, and a relatively 
wide anterior sphenoidectomy is performed with a rongeur or high-speed drill. 
Anatomical landmarks of the sphenoid roof (septae, carotid and optic 
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protuberances, opto-carotid recess, sellar floor, etc.) can then be identified. 
Once the nasal phase of the approach has been completed, all modifications of 
microscopic techniques continue in an identical manner for PA removal. The 
sellar floor is next opened, exposing the dura mater and the borders of the 
venous sinuses laterally and infero-superiorly. When in doubt, the position of 
the carotid artery can be confirmed with micro-Doppler before incision of the 
dura [90]. Ideally, the pituitary gland, its capsule (pial surface), and the tumor 
should be left intact at this phase. In case of a microadenoma, the tumor is 
carefully localized, if necessary reviewing the preoperative images once more, 
before incising the capsule of the pituitary gland. PAs are surrounded by a 
pseudocapsule, which serves as an excellent cleavage plane for dissection 
around the adenoma tissue to be excised [15]. The tumor with its capsule is 
removed using suction, ring curettes, and pituitary rongeurs of appropriate 
sizes and angles. In case of a large macroadenoma, an internal decompression 
is usually necessary before a cleavage plane can be developed around the 
adenoma. At this time, the tumor removal and dissection is started infero-
laterally and working posteriorly, leaving the antero-superior part untouched 
as long as possible. After no more tumor is seen, an (assisting) endoscope can 
be utilized to look for tumor remnants around the corners [95]. 
Once the removal is completed, cerebrospinal fluid (CSF) leakage is 
looked for and if necessary confirmed with the Valsalva maneuver. There are 
various protocols for closing the sellar floor. Generally, the more voluminous 
the CSF leakage is detected, the more meticulous the patching and 
reconstruction of the sellar floor [96]. In case of no leakage, the dural access 
site can be covered with a sponge or equivalent to offer some scaffolding for 
vascularized (pseudo)dural regrowth. If the CSF leakage is generous, an 
autologous fascia-fat graft (harvested from the thigh or abdomen) and a piece 
of titanium mesh, porous plastic, or bony septum (vomer) are placed in a 
multilayer and watertight manner to cover the sellar floor defect. Usually, the 
reconstruction is covered with glue to seal and offer some support for the 
patching material. Additionally, a spinal drain may be used for a few days to 
eliminate any excess intracranial pressure at the repair site. 
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4.2.2. Endoscopic technique 
The endoscopic technique has been well described by a number of groups 
[6, 91, 97, 98]. Using the keywords “endoscopic transsphenoidal surgery” 
retrieves approximately 800 illustrative operative videos from YouTube 
(September 2015). Compared with the microscopic technique, the advantages 
of endoscopy include minimal access with less dissection of the nasal 
structures, a panoramic view of the operative field, an improved lateral view 
with angled optics, and more versatility for accessing different and extensive 
lesions around the anterior cranial base. For these reasons, the endoscopic 
technique has largely replaced the microscopic technique [99]. 
Endoscopic endonasal access uses one or both nostrils as a natural corridor 
to reach the sphenoid sinus. Surgery usually commences via the right nostril 
by introducing a rigid 4 mm, 0° endoscope with an irrigation sheath. The 
middle turbinate is lateralized and the sphenoid ostium localized. In cases with 
a narrow nostril or a large tumor, or if the surgeon prefers, a left-sided route 
may also be created to work binarially. A nasoseptal flap is raised as necessary 
for later reconstruction of the sellar floor [100, 101]. In a typical PA surgery, 
with no need for nasoseptal flap, the mucosa around the sphenoid ostium is 
coagulated and the bone is removed with a rongeur to create a sufficiently 
wide sphenoidectomy to insert the endoscope and instruments into the 
sphenoid cavity. The endoscope may be then fixed with an adjustable holder 
mildly stretching the nostril upwards to allow space for the instruments 
working below. Alternatively, the assistant can hold the optics, allowing 
constant fine adjustments as necessary, to keep the surgical focus in the middle 
of the screen. From this point, the procedure continues in the same fashion as 
in the microscopic technique until no more tumor is seen. To complete the 
tumor removal, 30° and 45° optics are introduced, as necessary, to visualize a 
possible tumor residual. Reconstruction of the sellar floor follows the same 
principles as in the microscopic technique. 
The main disadvantage of the endoscopic technique is a lack of 
stereoscopic vision, which can be compensated by moving the optics to and 
fro as necessary, using instruments with depth markings (e.g. mark 10 mm 
from the tip) and repetitive training of hand-eye coordination [102]. The first 
versions of 3D endoscopic instrumentation are already available, and 
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undoubtedly, it will eventually replace the current 2D endoscopic equipment 
[7, 103]. 
4.3. Craniotomy 
Tumor extensions into the retrochiasmatic area, posterior fossa, or 
temporal or frontal lobe have traditionally been regarded as contraindications 
for the transsphenoidal approach. This rule does not necessarily apply to the 
endoscopic endonasal approach, which has improved transsphenoidal access. 
Its extended modifications enable access into most parasellar areas, and 
sufficient tumor control can be achieved in many giant PAs [104], decreasing 
the need for open craniotomy. However, complete removal of an invasive, 
laterally stretching large adenoma is a complex task for any pituitary surgeon 
or approach. 
A large dumbbell-shaped adenoma with firm consistency and suprasellar 
adherence to neurovascular structures is often difficult to remove with a 
transsphenoidal approach. Dissection of critical structures may place the 
patient at considerable risk. Under these circumstances, a staged 
transsphenoidal approach may be advisable. The first session includes a safe 
resection of the lower portion of the tumor. The adherent suprasellar part of 
the tumor usually descends into the sella during the following months, offering 
itself for easier removal through redo transsphenoidal surgery instead of a 
transcranial approach [105]. 
Specific features favoring to elect the transcranial open craniotomy over 
the transsphenoidal route are exceptional supra- or retrosellar or lateral 
extensions of the tumor, hard tumor consistency, brain edema and invasion, 
and encasement of cerebral arteries or visual apparatus [106]. Especially 
multilobular shape and extension past the lateral wall of the cavernous sinus 
are beyond the scope of transnasal surgery [104]. 
There are several modifications of anterior/anterolateral transcranial 
approaches to the sellar area such as pterional frontotemporal or subfrontal 
craniotomies [107]. A more complex extradural approach for pituitary tumors 
is described by Dolenc [108]. The size and the direction in which the adenoma 
extends/invades will dictate the appropriate cranial approach in individual 
cases. However, a transcranial operation places the adjacent frontal lobe(s), 
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cranial nerves, vascular structures, and neuroendocrine pathways 
(hypothalamus, pituitary stalk) at risk. Since larger tumors are more likely to 
be treated with the transcranial approach, an unbiased comparison of results 
and complications with the transnasal approach is difficult. Reports comparing 
the approaches are conflicting regarding visual outcome, but the transnasal 
technique seems to offer superior results in terms of recovery of pituitary 
function and less frequent new hormonal dysfunction [109]. 
The choice between the transsphenoidal and transcranial approach is 
usually made case-by-case, taking into account the characteristics of the tumor 
and the patient, and the expertise of the surgical team. The techniques should 
be seen as complementary, rather than oppositional. They can even be applied 
simultaneously during the same surgical session [110]. 
 
4.4. Intraoperative adjunctive methods 
Neuronavigation. Initially, with the advent of the microscopic transsphenoidal 
technique, fluoroscopy was introduced by Guiot and Hardy to guide the 
operative approach to the sella [111]. By the end of the 1990s, image guidance 
for neurosurgery (neuronavigation) was available for intracranial operations, 
including transsphenoidal surgery [112]. The main advantage of 
neuronavigation over traditional fluoroscopy is multiplanarity (enabling 
especially midline orientation). Neuronavigation has most likely increased 
safety during the transsphenoidal approach, particularly in cases with aberrant 
nasal and skull base anatomy, where the pituitary surgeon may get lost and in 
worst case scenario end up damaging e.g. the carotid artery. Large variation 
exists in how and when neuronavigation is used in different pituitary centers 
[12]. 
Intraoperative MRI. The concept of intraoperative MRI was introduced at 
the end of the 1990s [113]. Intraoperative MRI enables detection of possible 
residual tumor when no more tumor is visible in the operative field through the 
microscope or endoscope. This gives the surgeon an immediate second chance 
to complete the resection. Intraoperative MRI is shown to be a feasible adjunct 
in transsphenoidal surgery, and reports suggest improved rates of complete 
resection and higher extent of tumor removal even in combination with the 
 40 
endoscopic technique [114, 115]. However, tiny tumor remnants may be 
hidden in the sellar circumference and can be below the detection level of MRI 
[116]. Another drawback is the major investments (millions of euros) required 
for establishing this sophisticated form of intraoperative visualization [117]. 
5. Radiotherapy 
Radiotherapy can be delivered as conventional external beam radiation therapy 
in fractions (conventional radiotherapy) or as stereotactic radiotherapy (STR), 
which can be delivered as a single shot or fractionated treatment. STR is 
delivered using stereotactic methods for high precision. The most common 
STR systems are cobalt-based (e.g. Gammaknife) and linear accelerator-based 
(e.g. Novalis and Cyberknife) [8]. STR is best suited for spherical PAs with a 
diameter of less than 3 cm. Historical series of less focused conventional 
radiotherapy show significant long-term side-effects, such as hypopituitarism 
and temporal lobe atrophy, in patients treated for PA [118]. Modern planning 
and targeting techniques have increased the safety and accuracy of external 
beam radiotherapy. It is currently indicated in larger PAs, which are not 
suitable for STR [8]. 
The literature does not support the routine use of radiotherapy as a primary 
treatment for PAs. However, very old or medically ill patients deemed 
unsuitable candidates for surgery may be considered for STR as an initial 
treatment [119]. STR is typically utilized in NFPA patients with substantial 
residual tumor or recurrence after transsphenoidal operation. It seems to be 
very efficient for this indication, with tumor control rates ranging from 83% to 
100% [8]. 
STR may be employed for selected patients with FPAs who have not 
achieved endocrine remission after surgery. In Cushing’s disease, the reported 
response to STR has been quite variable, with a mean of 51% (range 0-100%) 
of patients achieving remission. The mean time from treatment to remission 
has been 12 months [120]. Similarly, unsuccessful transsphenoidal surgery for 
acromegaly may be an indication for STR, unless long-term medical therapy is 
chosen. Some treatment-resistant GH-producing adenomas may require 
multimodality management, including STR. The reported rate of hormonal 
remission after STR for acromegaly is on average 45% (range 0-82%), with a 
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mean time to remission of 24 months [8]. Prolactinomas are primarily and 
efficiently managed with medical treatment. Drug-resistant cases are rare and 
possibly represent a biologically different subgroup of prolactinomas. Post 
STR remission rates are lower than in other FPAs, with a median of 35% 
(range 0-100%) [8]. 
Single-session STR margin doses have been on average 16 Gy and 22-24 
Gy for NFPA and FPA, respectively. New or worsening hypopituitarism after 
STR has been reported in 9% and 15-24% of NFPA and FPA patients, 
respectively [8]. Higher margin dose probably explains the difference in 
hypopituitarism between NFPA and FPA. Using fractionated STR for various 
PAs with at an average dose of 45 Gy (range 45-54 Gy) in 25 fractions, 
hypopituitarism was noted in 40% of cases, but the effect of preceding surgery 
was included [121] 
6. Outcome after transsphenoidal surgery 
6.1. Tumor control 
Success of surgery for functional adenoma is primarily determined by 
hormonal remission, and radiological extent of resection is a secondary 
measure of tumor control. All patients harboring FPA should be evaluated for 
hormonal cure after surgery using consensus guidelines and criteria [39, 48]. 
Reported rates of remission are primarily dependent on FPA subtype [122]. 
Sensitive hormonal assays may detect secretory tumor residuals even if 
postoperative high-quality MRI is negative [75]. 
The main objective of NFPA surgery is to decompress the optic nerve(s) 
and chiasm. This goal may be achieved even if some tumor is left behind, 
unlike in FPA, when residual tumor inevitably causes surgical failure as 
hormonal hypersecretion continues. Tumor control of NFPA is presented as 
the success rate of gross total resection or extent of resection. Quality of 
resection has gradually improved over time, and currently complete removal 
of NFPA is accomplished in more than 50% (up to 95%) of cases [64, 68]. The 
two strongest independent risk factors for incomplete resection are larger 
tumor size and higher grade of lateral tumor invasion [68, 123, 124]. 
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Several studies have made comparisons between endoscopic and 
microscopic outcomes in terms of tumor control, but have found no significant 
differences [11, 122, 125, 126]. To date, no randomized controlled 
comparisons exist, but one controlled single-center study reported improved 
tumor control with the endoscopic approach relative to the microscopic 
approach [9]. Most authors conclude that the quality of resection is highly 
dependent on the surgical experience, with better outcome correlating with a 
higher number of operated cases [127, 128]. 
6.2. Pituitary function 
Recovery and/or loss of hormonal function are well-known consequences of 
transsphenoidal surgery for PA. Postoperatively, improved function of the 
anterior pituitary has been reported in 33-50% of patients [129-132]. New or 
worsening anterior pituitary insufficiency has ranged from 1% to 33%. 
Permanent DI has been reported in 0.4-8.8% of cases, but it generally occurs 
in under 3% of cases [131, 133-137]. Transient forms of DI are much more 
common and have been noted in up to 50% of patients in some reports [136]. 
Larger tumor size, transcranial technique, and limited surgical experience 
have been factors leading to deteriorating pituitary function [131, 133, 138]. 
As can be expected, these factors correlate inversely with the probability of 
improving pituitary function [131, 138, 139]. In addition, endoscopic 
technique, younger age, absence of systemic hypertension, absence of tumor 
invasion, and hyperprolactinemia secondary to stalk compression have been 
suggested to improve chances for recovery of pituitary function [9, 131, 138]. 
Adenoma subtype may have an impact on postoperative hormonal recovery 
since adrenal insufficiency was reversed more often in acromegalic patients 
than in NFPA patients, independent of tumor size or invasion [140]. 
Successful surgery for Cushing’s disease leads to transient secondary 
adrenal insufficiency in a majority of patients. In most cases, adrenal 
responsiveness is restored to normal over a period of several months to one 
year [141-144]. Poorer recovery of function and higher rates of 
hypopituitarism are related to partial hypophysectomy, which is sometimes 
required for hormonal remission in Cushing’s disease [145]. 
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The overall variability in reported rates of altered pituitary function reflects 
several factors, including different surgical strategies with respect to normal 
gland manipulation and preservation, transsphenoidal surgical experience, 
tumor size, and hormonal testing protocols and the criteria for improved or 
deteriorated function. 
6.3. Neuro-ophthalmological function 
Successful transsphenoidal surgery for PA will usually improve deficient 
visual function or even restore it to normal. There is a strong correlation 
between improvement of visual acuity and visual field recovery, but outcomes 
are not parallel in every case. Postoperative improvement of visual fields is 
reported in 77-95% of cases, and no improvement or deterioration in 8-19% of 
cases [146-148]. Reported rates of improved visual acuity are clearly more 
variable, ranging from 45% to 81% [148, 149]. 
Although visual function can recover several years after surgery, most of it 
returns within the first 6 months [147]. Longer history and larger degree of 
visual impairment are linked with worse recovery. Thus, prompt diagnosis and 
early, even prophylactic, surgery is recommended in patients with PA [147]. 
Permanent visual deterioration caused by surgical manipulation is very rare, 
usually reported in less than 1% of cases [10, 123]. 
6.4. Complications 
Contemporary techniques of transsphenoidal surgery are considered relatively 
safe, and operative mortality is less than 0.5% according to a meta-analysis 
[10]. The potential complications of transsphenoidal pituitary surgery are 
varied. They are related to nasal dissection, opening of the sellar floor, 
manipulation of the pituitary gland and/or stalk, and intracranial vascular and 
neural injury. Lack of uniform grading or classification systems complicates 
comparison and interpretation of the literature. 
Except for hormonal impairments (hypopituitarism), the most commonly 
quoted complication is nasal CSF leakage ranging from 1% to 9% (pooled rate 
7%) [7, 10, 86, 133, 150]. The main risk factor for postoperative CSF 
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rhinorrhea is intraoperative disruption of the arachnoid membranes. Other 
suggested risk factors are larger tumor size, age (both younger and advanced), 
body mass index, repeat operation, and previous radiotherapy [151-154]. 
A serious consequence of CSF leakage is postoperative meningitis, which 
is reported in between 0-2% of cases [10, 133]. Syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH) may complicate pituitary surgery 
in up to 35% of cases, and typically presents approximately one week 
postoperatively [155, 156]. 
The most feared morbidity related to transsphenoidal surgery is caused by 
injury to the vasculature or the cranial nerves. Loss of midline orientation and 
consequent carotid artery injury or inappropriate handling of para/suprasellar 
vessels are the two most common reasons for vascular complications, 
occurring in about 1% of surgeries [10]. Cranial nerve injury is related to 
attempts to remove lateral tumor remnants from the cavernous sinus. 
Permanent cranial nerve damage is rare, occurring in only 0.5% of cases [10, 
133]. 
Minor sinonasal complaints, such as nasal congestion, crusting, and altered 
smell/taste, are common (up to 60%), but are often self-limiting [42]. Major 
epistaxis or sinusitis requiring treatment is rare, generally reported in 0.6-2% 
and 0.4-2% of cases, respectively [90, 102, 137, 157]. A small meta-analysis 
found rhinological complications in up to 13% of patients after microscopic 
surgery compared with 1.2% after endoscopic surgery [126]. By contrast, in a 
retrospective analysis of acromegalic patients having undergone microscopic 
or endoscopic transsphenoidal surgery [158] the self-reported incidence of 
alterations in taste or smell was 26% versus 5% (P=0.008), and in sinusitis 
26% versus 3% (P=0.002). The authors concluded that sinonasal 
complications could be regarded as a natural consequence of operative 
manipulation and dissection associated with both techniques. Increasing 
awareness of this complication and consequently more active inquiry and 
recording may also explain the higher incidence. In addition, acromegalic 
patients often report preoperative sinonasal complaints as one feature of their 
morbid condition [42]. 
Many authors have found surgical experience in terms of a higher number 
of performed operations to be a significant factor in a lower rate of 
complications [102, 127, 133, 154]. However, the superiority of one 
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transsphenoidal technique over the other with respect to rate of complications 
has been much more difficult to demonstrate [10, 159, 160]. 
7. Health-related quality of life after treatment for 
pituitary adenomas 
7.1. Measuring health-related quality of life 
The WHO definition of health is based on physical, mental, and social well-
being. Health-related quality of life (HRQoL) can be defined as the functional 
effect of an illness and its consequent therapy on a patient, as perceived by the 
patient. This is further modified by the patient’s individual goals, expectations, 
standards, concerns, and cultural context. No gold standard exists for 
measurement of HRQoL. Commonly, a self-administered questionnaire-based 
method (instrument) is used. The HRQoL instrument may describe one’s 
health in different dimensions (profile) or as a single index (total score). It can 
either be generic, disease-specific, or domain (e.g. fatigue, anxiety) -specific. 
Generic questionnaires can be used to measure HRQoL regardless of the 
disease or medical condition, and different patient groups can be compared 
with each other. Additionally, generic instruments are utilized for assessing 
quality-adjusted life-years (QALYs). Examples of common generic 
questionnaires are the Short-Form health survey (SF-20/36/SF-6D), the 
Nottingham Health Profile (NHP), the European Quality of Life Scale (EQ-
5D), the 15D, the General Well-Being Schedule (GWBS), the WHO Disability 
Assessment Schedule (WHODASII), and the General Health Questionnaire 
(GHQ)-12/28/30 [161, 162]. 
The Finnish 15D questionnaire is a generic HRQoL instrument that 
combines the advantages of a profile and a preference-based, single index 
measure [163]. It is a comprehensive (15-dimensional) questionnaire that can 
be completed within 5-10 minutes. The 15D instrument has been applied in 
drug evaluations, surgical outcome studies, assessment of rehabilitation 
results, and many other medical treatments and conditions including PA. 
There are currently (as of September 2015) 370 peer-reviewed publications 
 46 
using the 15D instrument (http://www.15d-
instrument.net/service.cntum?pageId=110293). 
Disease-specific questionnaires have been developed to increase the 
sensitivity for detection of impairments and changes associated with a 
disorder. Such instruments for specific pituitary purposes are available for 
Cushing’s disease [164], acromegaly [165, 166], and hypopituitarism [167, 
168]. 
Numerous domain-specific questionnaires are available for measuring the 
effect of particular symptoms or functions on a patient’s HRQoL regardless of 
etiology. Examples of domain specific questionnaires used for PA patients are 
the Hospital Anxiety Depression Scale (HADS), the Multidimensional Fatigue 
Inventory (MFI-20), and the Major Depression Inventory (MDI) [162]. 
Unfortunately, there has been little consistency in measuring the HRQoL 
in PA patients. At least 49 different questionnaires have been applied to assess 
the HRQoL, and only a minority of cross-sectional reports have used an age 
and gender-adjusted control population [162]. 
7.2. Health-related quality of life and functional pituitary adenoma 
Prolactinoma. Relatively few studies on HRQoL after treatment of 
prolactinoma have been published [162]. The largest study, including 128 
prolactinoma patients, suggested a trend towards impaired HRQoL total score 
(SF-36) after treatment (27% surgery) relative to a control population, but no 
statistical significance was detected [169]. Moreover, no independent factors 
for compromised HRQoL scores were found either. 
Another study on female patients (n=55) treated exclusively with 
dopamine agonists for microprolactinoma (67% in remission) suggested 
increased anxiety and depression score in HADS, increased fatigue on most of 
the subscales of the MFI-20, and worse scores on social functioning in both 
SF-36 and HADS [170]. Outcomes were compared with an age-matched 
control population (e.g. friend, neighbor) provided by each patient.  The 
authors found no correlation between HRQoL scores and age, prolactin level, 
present use of dopamine agonist, or hypogonadism. 
A Brazilian study showed poorer HRQoL score in prolactinoma patients 
treated with dopamine agonists (n=50) than in a healthy control population 
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(hospital staff). Patients in biochemical remission (50%) showed statistically 
better HRQoL scores than patients with hyperprolactinemia (50%) [171]. 
A Finnish study reported multiple HRQoL (15D) impairments in surgically 
treated prolactinoma patients compared with age- and sex-adjusted controls. 
The authors did not find any correlation between postoperative 
hyperprolactinemia and 15D score, but their cohort consisted of only 17 
patients [172]. 
In conclusion, especially mental health and psychological function 
measures have been impaired in prolactinoma patients. Larger studies 
including gender- and age-adjusted control populations are needed. 
 
Acromegaly. Many cross-sectional studies have shown severe impairments of 
HRQoL in patients treated for acromegaly [173-176]. A disease-specific 
questionnaire (AcroQoL) has indicated compromised HRQoL on all subscales: 
appearance, physical performance, psychological well-being, and personal 
relations [165, 174, 176].  
The largest study on HRQoL of acromegalic patients (n=231) used the 
generic 15D instrument [175]. The main finding was reduced total HRQoL 
score in patients treated for acromegaly compared with the age- and gender-
standardized control population. The strongest independent negative factors 
for HRQoL were advanced age, higher BMI, and radiotherapy. Interestingly, 
the 15D score was related to nadir GH in oral glucose tolerance testing in an 
inverted U-shape: lower or higher GH-values were associated with worse 
HRQoL score relative to values between 0.3 and 1.0 µg/L. 
Slowly progressive disease with often delayed diagnosis may cause 
irreversible changes in appearance and internal tissues, which has been 
reflected in impaired HRQoL in acromegalic patients even after successful 
treatment and biochemical remission [174]. However, several studies have 
shown that control of GH/IGF-1 excess by surgery or medical treatment has 
improved the HRQoL score [165, 175-177]. Remission after surgery alone is 
related to a better HRQoL outcome than surgery followed by SSA treatment 
[178].  
The need for postoperative SSA medication has been shown to be 
correlated with worse HRQoL score despite similar IGF-1 levels [172, 179]. A 
small (n=20) placebo-controlled, double-blinded crossover study suggested 
that addition of pegvisomant treatment for biochemically controlled (IGF-1 
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normal for age) patients receiving SSA improved their QoL [166]. Thus, 
normalized IGF-1 values did not necessarily guarantee optimal HRQoL. 
However, this result has not been repeated in any other study. 
In summary, HRQoL may be impaired in acromegaly despite disease 
control, and independent factors associated with better outcome need further 
investigations [162]. Table 1 presents the results of selected studies (based on 
size and publication year) of HRQoL after treatment of acromegaly. 
 
Cushing’s syndrome/disease. A review of 22 studies, including a total of 1713 
patients harboring Cushing’s syndrome, suggests a clearly negative impact on 
HRQoL as compared with healthy controls or reference values [162]. 
Cushing’s syndrome has been reported to impair HRQoL on many 
dimensions: physical functioning, bodily pain, mental and general health, and 
anxiety [169, 180]. Authors mostly agree that there are no differences in 
HRQoL between patients with Cushing’s syndrome of adrenal or pituitary 
origin [181-183]. 
Several studies show poorer HRQoL independently of treatment modality 
and biochemical remission, possibly explained by chronic hypercortisolemia 
preceding treatment [183-186]. However, patients show improvements after 
treatment, and a better HRQoL score has correlated with biochemical 
remission, especially in the disease-specific questionnaires [3, 180, 182, 187]. 
Presence of depression had a lowering effect on HRQoL in two large 
studies using disease-specific questionnaires [3, 181]. Other factors negatively 
influencing HRQoL in Cushing’s disease have been older age, female gender, 
hypopituitarism, and shorter duration of remission, but the literature is 
inconsistent [162, 164, 182, 184]. 
Disease remission after successful treatment with subsequent gradual 
improvement in HRQoL has been the most consistent finding in studies using 
either generic or disease-specific questionnaires for Cushing’s disease [164]. 
Table 1 presents the results of selected studies (based on size and publication 
year) of HRQoL after treatment of Cushing’s disease. 
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7.3. Health-related quality of life and nonfunctional pituitary 
adenoma 
Patients treated for NFPA have demonstrated some diversity in their HRQoL 
outcomes [162]. Most authors report decreased HRQoL relative to healthy 
controls or reference values, with pronounced impairments in both physical 
and mental measures [169, 188, 189]. By contrast, three reports found no 
differences in HRQoL between patients treated for NFPA and the control 
population or reference values [172, 190, 191]. As with prolactinomas, no 
disease-specific questionnaire has yet been developed for patients with NFPA, 
which could detect more specific or sensitive impairments in the disease. 
HRQoL in NFPA patients has been negatively influenced by impairments 
of visual function [190, 192], pain [192], sleep disturbances [189], older age 
[188, 190], female sex, tumor recurrence, hypopituitarism [188, 190, 192, 
193], and radiotherapy [190, 194]. Conversely, others have found no 
significant correlation with hypopituitarism [194] or radiotherapy [172, 188, 
193]. The inconsistency could be related to differences in patient groups, 
HRQoL instruments, criteria for hormonal deficiency, treatment, and 
multifactorial mechanisms regulating the perceived HRQoL. 
In summary, the literature suggests that near-normal HRQoL may be 
achieved in NFPA patients. This is supported by reports indicating higher 
HRQoL scores in patients harboring NFPA as opposed to FPA [169, 172]. The 
data on independent factors influencing HRQoL score after treatment of 
NFPA are conflicting and require further studies. Table 2 presents the results 
of selected studies (based on size and publication year) after treatment of 
NFPA. 
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8. Multidisciplinary collaboration 
Pituitary adenomas constitute a complex and diverse spectrum of disorders, 
which may involve multiple organs or body functions either directly or 
indirectly. State-of-the-art care for patients with pituitary adenomas is 
preferably offered in a multidisciplinary collaborative organization. Stepwise 
diagnostics, treatment and follow-up are best coordinated by an 
endocrinologist. 
Transsphenoidal pituitary surgery differs anatomically from mainstream 
transcranial neurosurgery. The transnasal route requires special skills and 
knowledge. A close cooperation between the pituitary surgeon and an 
otorhinolaryngologist familiar with endoscopic sinus surgery is particularly 
useful when operating on patients with pre-existing sinus disease, septal 
perforations, or septal deviations [102]. According to a recent international 
survey, pituitary surgery is conducted most commonly by a neurosurgeon or a 
team of neurosurgeons together with an otorhinolaryngologist, and in a few 
units is performed by the otorhinolaryngologist alone [12]. 
Pituitary surgery has anesthesiological features requiring special attention. 
Perioperative pituitary insufficiency and replacement therapy, where 
necessary, must to be considered. A difficult intubation must be anticipated in 
cases of acromegaly and sometimes in Cushing’s disease. Intraoperative blood 
pressure control contributes to adequate hemostasis and a bloodless surgical 
field. To push suprasellar tumor remnants down into the operative view, the 
anesthetist may use controlled hypercapnia and/or the Valsalva maneuver. 
Postoperative water balance needs careful monitoring for an often 
unpredictable course [195]. 
Pathological analysis of pituitary tumors has become complex, with the 
advent of novel categories defined by WHO [2]. Although most adenomas 
may be easily classified, others may require the expertise of a dedicated 
neuropathologist. Molecular signatures of pituitary adenomas using genomics 
and proteomics are being increasingly used to identify invasive and atypical 
tumors and to guide treatment [196]. 
Experienced pituitary practitioners in neurosurgery and endocrinology, 
together with teams from neuro-ophthalmology, neuropathology, neuro-
oncology, diagnostic and interventional neuroradiology, and 
otorhinolaryngological surgery, can constitute a center of excellence [128]. A 
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coordinated multidisciplinary approach and regionalized treatment centers are 
supported by data showing better outcomes in experienced hands with a 
sufficient number of cases treated [197]. 
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C. Aims of the study  
 
 
 
1. To describe the transitional phase from microscopic to endoscopic 
transsphenoidal surgery for nonfunctional pituitary adenoma and to 
clarify its effects on outcome at HUH during 2000-2010. 
 
2. To investigate health-related quality of life in patients operated on 
for a functional pituitary adenoma. 
 
3. To evaluate health-related quality of life in patients operated on for 
a nonfunctional pituitary adenoma. 
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D. Patients and methods 
1. Patients 
Over an 11-year period (from 2000 to 2010), 330 newly diagnosed pituitary 
adenoma patients were operated on at Helsinki University Hospital. 
Patients harboring a pituitary carcinoma (n=2), patients with a history of 
previous pituitary surgery (n=34), or patients undergoing a craniotomy (n=2) 
were excluded from the study. 
Publication I (Transition from microscopic to endoscopic transsphenoidal 
surgery for nonfunctional pituitary adenomas.): This study included 185 
patients operated on for a NFPA. Patients were divided into two groups: the 
Microscopic group (n=144) was operated on during the first 101 months and 
the Endoscopic group (n=41) during the last 31 months of the study period. 
Publication II (Normal long-term health-related quality of life can be 
achieved in patients with functional pituitary adenomas having surgery as 
primary treatment): This study included patients operated on for a FPA. A 
survey was sent to 128 patients, 100 of whom responded. Consequently, the 
actual study population comprised 47 patients with acromegaly, 21 patients 
with Cushing’s disease, 26 patients with prolactinoma, two patients with TSH-
adenomas, and four patients harboring gonadotropinomas. 
Publication III (Health-related quality of life in patients treated for non-
functioning pituitary adenomas during the years 2000-2010): This study 
included patients operated on for a NFPA.  A survey was sent to 161 patients, 
137 of whom returned the questionnaires. 
2. Data collection 
Publications I, II, and III: Data were collected retrospectively from medical 
reports and imaging studies. Informed written consent to gather follow-up data 
from other hospitals was obtained from all patients. Data collection ensued 
between January 2012 and June 2013. 
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Publications II and III: A 15D questionnaire assessing health-related quality of 
life (Appendices 1 and 2) and a supplementary survey assessing educational 
background, marital status, current medication, and major comorbidities (type 
1 and type 2 diabetes, essential hypertension, coronary artery disease, and 
depression) (Appendices 3 and 4) were sent to all patients alive at the 
beginning of 2013. One reminder was sent to nonrespondents two months 
later. 
3. Surgery 
All operations were performed by experienced neurosurgeons. An assistant 
surgeon was engaged infrequently. The transsphenoidal technique was 
modified in June 2008, and the microscope was switched to the endoscope, 
which was thereafter used solely. Fluoroscopy was used in all microscopic 
approaches. Neuronavigation was rarely used during the study period. 
The protocol and the instruments applied for tumor removal were alike in both 
approaches. An ultrasonic aspirator was not utilized. Intra- or postoperative 
lumbar drainage was rarely used. 
3.1. Microscopic approach 
The microscopic transseptal technique was applied. The mucosal incision was 
made at the anterior nasal septum, and the subsequent submucosal dissection 
continued up to the sphenoid ostia. A nasal speculum was used to maintain 
access between the septal mucosa. Anterior sphenoidectomy was done with 
rongeurs and/or a high-speed drill. The septae of the sphenoid sinus were 
removed, as necessary, and the sellar floor at the midline was identified. The 
sellar floor was removed and the dura incised to uncover the tumor/pituitary 
gland. A selection of suction, ring curettes, and pituitary rongeurs of 
appropriate sizes and angles was applied to excise the adenoma. Once the 
removal was completed, CSF leakage was carefully inspected. If leakage had 
occurred, an autologous fascia-fat graft was harvested from the thigh and 
placed in the sellar floor to seal the defect. 
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3.2. Endoscopic approach 
 
The endoscopic endonasal technique was used. The endoscope was introduced 
through nostril(s) and middle turbinate(s) lateralized as necessary to create a 
free passage for the instruments. The mucosa around the sphenoid ostium was 
coagulated and access into the sphenoid sinus created as in the microscopic 
approach. The endoscope was fixed with an adjustable holder, mildly 
stretching the nostril upwards to allow room for the instruments introduced 
below. When in doubt, the position of the carotid artery was established with a 
micro-Doppler before dural incision. From this point, the procedure continued 
in the same fashion as in the microscopic approach until no more tumor was 
seen. To complete the tumor removal, 30° and 45° optics were used, if 
necessary, to visualize any tumor remnant “around the corners” of the sellar 
opening. Steering of the angled endoscope was done freehand, usually with a 
curved-tip suction tube in the other hand. Alternatively, the angled endoscope 
was fixed in position to operate with both hands (two instruments). 
Reconstruction of the sellar floor was performed as in the microscopic 
approach. 
3.3. Postoperative care 
Immediate postoperative care and follow-up took place at the Neurosurgical 
Unit. Occasional CSF rhinorrhea (or its suspicion) was primarily managed 
with a lumbar drain, and only persistent leakage was sealed with repeat 
surgery. On the 2nd postoperative day, the Endocrine Unit took over the care 
for a further 2-3 days. Patients were observed and evaluated for continuation 
or discontinuation of perioperative hydrocortisone substitution, managed for 
possible water and electrolyte disturbances (diabetes insipidus), and usually 
discharged on the 5th or 6th postoperative day. 
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4. Endocrine assessment and care 
Pituitary function was assessed using in-house assays and clinical evaluation. 
Laboratory measurements were performed at the laboratory of Helsinki 
University Hospital (HUSLAB), and standard accredited assays were used. 
For study purposes, specific pituitary axes were classified as dysfunctional if 
they were substituted. All patients were re-evaluated during the first 
postoperative week, and the function of adrenal axis and posterior pituitary 
lobe was substituted as necessary. Three months after the surgery, patients 
came to the Endocrine Unit for more thorough evaluation (hypo- and 
hyperpituitarism) of relevant pituitary axes. The GHRH-arginine test (in 
addition to GH- and IGF-1 measurements) was a prerequisite for 
reimbursement of GH replacement therapy. All clinically significant 
deficiencies were substituted, unless contraindicated. Assessment of hormonal 
remission and optimization of treatment for acromegaly and Cushing’s disease 
were accomplished according to available international consensus criteria 
and/or scientific evidence [41, 48, 53, 198, 199]. For study purposes, hormonal 
remission was assessed according to the most recent criteria [39, 53]. During 
later follow-up patients were seen at the Endocrine Unit for hormonal 
assessment on a regular basis, usually once a year. 
5. Radiology 
The routine scanning protocol consisted of sagittal and coronal T1-weighted 
thin sliced sequences, with and without contrast media, using a 1.5 Tesla MRI. 
In case there was a contraindication for MRI, the imaging was done with 
computerized tomography. The tumor dimensions were measured (A: height, 
B: width, C: length), and the volume was estimated (ABC/2) independently by 
a radiologist (Kivisaari) and a neurosurgeon (Karppinen). Knosp classification 
was used for judging the lateral extension [76]. The Knosp grades 0 and 1 
suggest a noninvasive tumor and grades 2 to 4 increasing invasion of the 
cavernous sinus. In case of discrepant (Kivisaari vs. Karppinen) measurements 
or Knosp classification, the larger value or higher grade was used for study 
purposes. 
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Postoperative MRI was repeated at 3 and 12 months, and thereafter at 1- to 
3-year intervals, based on biochemical and clinical data/analyses. The quality 
of resection (total or subtotal) was based on assessment using the 3-month 
postoperative scan. The grading was done in favor of an existing residual, if 
postoperative artifacts prevented precise evaluation. Tumor remnant was 
measured in three dimensions, and the volume and residual percentage 
estimated. A recurrent tumor was defined as a new tumor growth in cases with 
initial total excision (no tumor detected at 3-month postoperative scan). A 
postoperative residual tumor was graded according to the Response Evaluation 
Criteria in Solid Tumors (RECIST) guidelines as progressive (at least 20% 
increase), stable, or shrunken (at least 30% decrease) during later follow-up 
[200]. 
6. Neuro-ophthalmology 
 
An experienced neuro-ophthalmologist assessed visual acuity and visual fields 
preoperatively in cases where impaired vision was confirmed by the patient 
when asked about it and/or the pituitary tumor was in contact with the optic 
nerve(s) or chiasm, as assessed by MRI.  All patients presenting with impaired 
visual fields and/or impaired visual acuity were re-examined postoperatively. 
Preoperative visual acuity/visual fields were classified as either normal or 
impaired. For study purposes, a single variable was formulated indicating 
either normal visual function or impaired function (any function, any degree). 
Furthermore, the postoperative outcome was categorized as “normal”, 
“normalized”, “improved”, “unchanged”, or “further impaired”. The 
postoperative assessment took place 3-12 months after surgery. 
7. Histopathology 
All tumor samples were verified according to WHO classification [2] as 
benign pituitary adenomas by an experienced neuropathologist. However, 
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immunohistochemistry (pituitary hormones, p53 and MIB-1) was not routinely 
performed during the first half of the study period. 
8. Statistical methods 
Results are given as mean, range, and standard deviation for continuous 
variables and as frequency for categorical variables. Data were analyzed using 
SPSS 22 (SPSS Inc., Chicago, IL, USA) software. The Tobit model was 
estimated with Limdep 7 (Econometric Software Inc., Plainview, NY, USA). 
Publication I: Pairwise comparisons of categorical variables were made using 
Fischer’s exact and x2 tests. The distributions of continuous variables were 
visually checked, and a subsequent log-transformation was used for operation 
time. The multivariate analysis was performed using linear and logistic 
regression analysis. Means among three or more groups were compared using 
one-way analysis of variance test (ANOVA). A p-value of  <0.05 was 
regarded as significant. 
Publications II and III: The statistical significances of the differences in the 
means of continuous variables between different groups were calculated using 
independent samples t-test. Pearson correlation coefficient was used in 
calculating correlations between continuous variables. A Tobit model was 
utilized to estimate the influence of different factors on HRQoL (15D score as 
dependent variable). A p-value of <0.05 was regarded as significant. 
9. Ethical aspects 
The study protocol was approved by the institutional review board and the 
local committee of ethics (registration no. 68/2012). Each patient gave signed 
informed consent for participation in the study. 
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E. Results 
1. Transsphenoidal surgery for nonfunctional pituitary 
adenomas – outcome after microscopic versus 
endoscopic resection 
1.1. Patient and tumor characteristics 
The study population comprised 144 patients in the Microscopic group and 41 
patients in the Endoscopic group. Preoperative patient characteristics are 
presented in Table 3 and preoperative tumor characteristics in Table 4. No 
statistical difference was found between the two groups in the reported 
variables. 
 
 
 
 
Table&3.&Preoperative&patient&characteristics& &
&& Microscopic( Endoscopic( All( p(
Patient(demographics( & & & &
n&(%)& 144&(78)& 41&(22)& 185&(100)& &
Male&%& 66& 56& 64& 0.25&
Mean&age&(Range)&{SD}& 58.4&(17F83)&{13}& 58.5&(16F86)&{16}& 58.4&(16F86)&{14}& 0.96&
Presenting(symptoms*(n((%)( & & & &
None&=Incidental& 50&(35)& 16&(39)& 66&(36)& 0.61&
Visual& 56&(39)& 14&(34)& 70&(38)& 0.58&
Hypopituitarism& 18&(13)& 5&(12)& 23&(12)& 0.96&
Apoplexy& 12&(8.3)& 3&(7.3)& 15&(8.1)& 0.83&
Headache& 22&(15)& 5&(12)& 27&(15)& 0.62&
Visual(deficit(n((%)( & & & &
Decreased&acuity**& 70&(57)& 20&(59)& 90&(58)& 0.70&
Visual&field&deficit***& 89&(65)& 29&(74)& 118&(67)& 0.48&
*patient&spontaneously&reporting,&multiple&may&apply& &
**data&missing&n=28& &
***data&missing&n=7& &
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1.2. Pituitary function 
The number of patients receiving hormone replacement therapy because of 
hypopituitarism preoperatively, at the 3-month postoperative follow-up, and at 
the last follow-up is presented in Table 5. 
Before surgery, normal pituitary function (defined by laboratory and 
clinical evaluation) was observed in 41% of patients in the Microscopic group 
and in 44% of patients in the Endoscopic group. Hydrocortisone replacement 
was initiated preoperatively for all patients with hypocortisolism (defined as 
morning serum cortisol <300 nmol/l). 
The effect of surgery on pituitary function (classified by laboratory and 
clinical evaluation) is presented in Table 6. At the 3-month postoperative 
follow-up, no significant differences were observed in overall incidence (any 
axis) or distribution of (specific axis) hypopituitarism between the groups 
(Table 5). 
By the end of follow-up, the need for replacement therapy had increased 
equally in both groups. 
 
Table&4.&Preoperative&tumor&characteristics& &
&& Microscopic( Endoscopic( All( p(
Mean(size((Range)({SD}( & & & &
Height&mm& 28&(8:60)&{10}& 27&(11:55)&{9}& 28&(8:60)&{10}& 0.75&
Volume&cc*&& 8.7&(0.5:44.7)&{8.2}& 6.4&(1.2:19.1)&{4.2}& 8.2&(0.5:44.7)&{7.6}& 0.38&
Invasion(n((%)( & & & &
Knosp&3:4& 83&(58)& 20&(50)& 103&(56)& 0.47&
*(height&x&width&x&length)/2& &
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Table&6.&Effect&of&surgery&on&pituitary&function&at&3&months&
Microscopic(
Preop(axis(function(
Unchanged&
(n)&
Improved&
(n)&
Normalized&
(n)&
Worse&
(n)&
Unknown&
(n)&
Overall&
(%)&
Normal&adrenal& 80& H& H& 16& H& Worse&17%&
Defect&adrenal& 21& H& 6& H& H& Improved&22%&
Normal&gonadal& 23& H& H& 6& 6& Worse&17%&
Defect&gonadal& 48& H& 12& H& 8& Improved&18%&
Normal&thyroid& 67& H& H& 24& 3& Worse&26%&
Defect&thyroid& 36& 1& 5& 1& H& Improved&14%&Worse&2%&
TOTAL( 275& 1& 23& 47& 15& Improved(7%(Worse(13%&
&
Endoscopic(
Preop(axis(function( &
Normal&adrenal& 20& H& H& 5& H& Worse&20%&
Defect&adrenal& 10& 1& 4& H& H& Improved&33%&
Norm&gonadal& 8& H& H& H& 1& Unchanged&
Defect&gonadal& 13& & 4& & 1& Improved&22%&
Normal&thyroid& 22& H& H& 4& H& Worse&15%&
Defect&thyroid& 11& H& H& H& H& Unchanged&
TOTAL( 84& 1& 8& 9& 2& Improved(9%(Worse(9%&
Table&5.&Hormonal&replacement&therapy&
&& Microscopic( Endoscopic( All(
Hormonal(
replacement(n((%)( Preop& 3&months&
Last&follow9up&
(Mean&
81&months)&
Preop& 3&months&
Last&follow9up&
(Mean&
26&months)&
Preop& 3&months&
Last&follow9up&
(Mean&
69&months)&
Any&(>0)& 52&(36)& 85&(51)& 97&(69)& 20&(49)& 25&(51)& 29&(71)& 72&(39)& 110&(51)& 126&(69)&
Cortisol& 33&(23)*& 45&(32)& 45&(32)& 17&(42)*& 16&(39)& 15&(37)& 50&(27)& 61&(34)& 60&(33)&
Testosterone#& 12&(13)& 38&(41)& 46&(50)& 6&(26)& 12&(52)& 14&(61)& 18&(15)& 50&(44)& 60&(52)&
Thyroxin& 33&(23)& 68&(49)& 88&(62)& 13&(32)& 20&(49)& 22&(54)& 46&(25)& 88&(49)& 110&(60)&
GH& 0&(0)& 1&(0.7)& 7(5.0)& 0&(0)& 0&(0)& 1&(2.4)& 0&(0)& 1&(0.6)& 8&(4.4)&
ADH& 1&(0.7)& 10&(7.1)& 7&(5.0)& 0&(0)& 0&(0)& 0&(0)& 1&(0.5)& 10&(5.5)& 7&(3.8)&
*&p=&0.02&
#&men&only,&in&a&majority&of&patients&with&low&testosterone&levels&preoperatively,&replacement&therapy&was&not&initiated,&but&the&need&for&replacement&
therapy&was&re9evaluated&postoperatively.&
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1.3. Perioperative findings 
The mean operative time in the Microscopic group was 93 minutes and in the 
Endoscopic group 105 minutes (p=0.13). Multivariate regression analysis 
suggested that, large tumor size (p<0.0005) and endoscopic technique 
(p=0.03) prolonged the mean operative time, in contrast to Knosp grade 
(p=0.45). 
A carotid injury occurred in two cases (1.4%) in the Microscopic group. 
Both hemorrhages were managed by applying tamponage to the bleeding site. 
No vessel injuries ensued in the Endoscopic group. 
The incidence of intraoperative CSF leakage was comparable in the 
Microscopic and Endoscopic groups (41% vs. 37%). 
1.4. Extent of resection 
The quality of resection is presented in Table 7. There was a uniform trend 
towards improved tumor control in the Endoscopic group, which did not, 
however, reach statistical significance. The multivariate analysis of the entire 
series suggested that larger preoperative tumor size (p=0.02) and higher Knosp 
classification (p<0.0005) reduced the chance of gross total removal. Higher 
Knosp grade significantly impaired the quality of resection in the Microscopic 
group only (p<0.0005) when groups were analyzed separately in the 
multivariate regression model. 
The distribution of residual tumor location was similar in both groups. 
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1.5. Visual outcome 
The visual function (acuity and fields) improved in a high number (82-94%) of 
patients. No statistical difference emerged between the groups. Postoperative 
worsening of visual function was detected in only one case in the Endoscopic 
group. This patient had severe visual impairment already preoperatively. 
1.6. Operative complications 
Postoperative complications are presented in Table 8. The occurrence of 
complications between the Microscopic and Endoscopic groups was similar. 
Three cases (2.1%) of permanent DI were detected in the Microscopic group, 
and none in the Endoscopic group. Postoperative CSF leakages were managed 
with reoperation. 
No postoperative mortality (within 30 days) occurred. 
Table&7.&Quality&of&resection&at&35month&follow5up& &
&& Microscopic( Endoscopic( All( p(
Extent(of(tumor(removal( & & & &
Gross&total&n&(%)& 64&(45)& 23&(56)& 87&(47)& 0.14&
Gross&total&%&
Over&2cm& 39%& 50%& & 0.32&
Knosp&354& 25%& 35%& & 0.41&
Mean&residual&%&(Range)&{SD}& 18&(1596)&{21}& 14&(1564)&{17}& 18&(1596)&{21}& 0.19&
Mean&residual&volume&cc&(Range)&{SD}& 3.1&(0.04527)&{5.9}& 1.2&(0.0259.0)&{2.1}& 2.8&(0.02527)&{5.4}& 0.20&
Location(of(residual(tumor(n((%)( & & & &
Intrasellar& 9&(12)& 0&(0)& 9&(10)& 0.21&
Suprasellar& 8&(11)& 4&(22)& 12&(13)& 0.31&
Lateral& 42&(56)& 10&(56)& 52&(56)& 0.69&
Supra& &Lateral& 13&(17)& 4&(22)& 17&(18)& 0.89&
Infrasellar/Clivus& 3&(4.0)& 0&(0)& 3&(3.2)& 0.35&
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1.7. Long-term tumor control and adjunctive treatment  
The mean radiological follow-up times were 68 months in the Microscopic 
group and 22 months in the Endoscopic group. Tumor control with count and 
timing of repeat surgery or radiotherapy are presented in Table 9. 
 Only one true recurrence (0.5%) was detected in the Microscopic group at 
55 months. Residual tumors demonstrated progressive growth in 51 cases 
(36%) in the Microscopic group and in 4 cases (10%) in the Endoscopic 
group. 
Repeat surgery was performed in cases of a large stable remnant causing 
compression of the optic chiasm (13 patients (9%) in the Microscopic group 
and 2 patients (5%) in the Endoscopic group) or a progressive tumor growth 
(2nd or 3rd surgery in 8 (6%) and 5 (3%) cases, respectively, in the Microscopic 
group). 
Radiotherapy was administered due to progressive tumor growth to 14 
patients (10%) in the Microscopic group and to 2 patients (4.8%) in the 
Endoscopic group. In 14 (10%) and one (2.4%) patient, respectively, the 
progressive tumor growth was managed with repeat surgery combined with 
radiotherapy. 
Table&8.&Postoperative&complications! &
&& Microscopic! Endoscopic! All! p!
Complication!n!(%)! & & & &
DI&(transient& &permanent)& 11&(7.6)& 2&(4.9)& 13&(7.0)& 0.54&
CSF&leak& 5&(3.5)& 1&(2.4)& 6&(3.2)& 0.74&
Meningitis& 1&(0.7)& 0&(0)& 1&(0.5)& 0.59&
Epistaxis& 3&(2.1)& 0&(0)& 3&(1.6)& 0.45&
Diplopia& 3&(2.1)& 0&(0)& 3&(1.6)& 0.35&
Postoperative&hemorrhage& 1&(0.7)& 0&(0)& 1&(0.5)& 0.59&
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2. Health-related quality of life (15D) after 
transsphenoidal surgery for pituitary adenomas 
2.1.  Characteristics of the study cohort  
Patient characteristics of both functional (n=100) and nonfunctional (n=137) 
pituitary adenoma cohorts at the time of survey (mean 7.4 years after 
transsphenoidal surgery) are presented in Table 10. At the time of survey, 44% 
and 62% of FPA and NFPA patients, respectively, required hormonal 
replacement therapy of at least one axis. The mean daily thyroxine dose was 
110 µg (range 50-200 µg) and 103 µg (range 25-175 µg), respectively. The 
Table&9.&Tumor&control&and&adjunctive&treatment&during&follow&up.&No&statistical&testing&between&the&groups&due&to&
different&follow;up&times.!
& Microscopic! Endoscopic! All!
Radiological!follow!up!(Range)!{SD}! & & &
Months! 68&&(3.5;151)&{34}& 22&(12;53)&{10}&
58&(3.5;151)&
{36}&
Tumor!control!n!(%)! & & &
No&tumor& 64&(45)& 24&(59)& 88&(48)&
Stable&residual& 21&(15)& 12&(29)& 33&(18)&
Progressive&residual& 56&(39)& 5&(12)& 61&(33)&
Recurrent&tumor& 1&(0.7)& 0&(0)& 1&(0.5)&
Adjunctive!treatment!n!(%)! & & &
2nd&operation& 23&(16)& 3&(7.3)& 26&(14)&
3rd&operation& 5&(3.5)& 0&(0)& 5&(2.7)&
Radiotherapy& 28&(20)& 3&(7.3)& 31&(17)&
Mean!time!to!additional!treatment!months!(Range)!
{SD}!
& & &
1st&to&2nd&surgery& 34&(0;124)&{34}& 10&(6;13)&{3.4}& 31&(0;124)&{33}&
2nd&to&3rd&surgery& 46&(0.1;109)&{49}& ;&
46&(0.1;109)&
{49}&
1st&surgery&to&radiotherapy& 49&(5.5;112)&{34}& 15&(6.7;19)&{7.0}&
46&(5.5;112)&
{34}&
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mean daily hydrocortisone dose was 15 mg (range 5-30 mg) and 14 mg (range 
5-25 mg), respectively. In total, 91% of patients treated for hormonally active 
adenoma were in remission. Visual function (both acuity and fields) was 
normal in 43% of patients treated for NFPA. 
The response rates (15D questionnaire) were 78% (100/128) and 74% 
(137/185) in the FPA and NFPA cohorts, respectively. No difference was 
present in characteristics of respondents and non-respondents. 
 
2.2. 15D and dimension scores compared with the control 
population 
The mean 15D score did not differ statistically between patients with FPAs 
and the control population (0.917 ±0.096 vs. 0.922 ±0.082, p=0.568). The 15D 
dimension profiles of the whole FPA cohort compared with the control 
population (n = 4924) are presented in Figure 2a. On single dimensions, the 
patients scored worse on speech and sexual activity, but slightly better on 
discomfort and symptoms than the control population. 
Table&10.&Characteristics&of&pituitary&adenoma&cohorts&
&
&
Acromegaly*&&&&&&&&&&&&&&&
(n=47)&
Prolactinoma&&&&&&&&&&&&&&&&&&
(n=26)&
Cushing's&
disease&&&&&&&&&&&&&&&&&&&&&&&&
(n=21)&
Gonadotropinoma&&&&&&&&&&&&&&&&&&
(n=4)&
Functional&
adenomas&
combined&&&&&&&&&&&&&&&&&&
(n=100)&
NonH
functional&
adenomas&
(n=137)&
Patient&demographics& && && && && && &&
Gender&(male/female)& 26/21& 10/16& 3/18& 2/2& 42/58& 92/45&
Mean&age&(years)**& 56.3&(±&12.5)& 47.3&(±&16.7)& 52.3&(±&12.8)& 48.3&(±&17.0)& 53.1&(±&1.4)& 64.2&(±&12.8)&
Mean&followHup&(yrs)& 7.7&(±&2.8)& 7.6&(±&3.4)& 6.9&(±&3.2)& 6.4&(±&3.6)& 7.4&(±&3.0)& 7.4&(±&3.2)&
Macroadenoma& 39&(83.0)& 21&(80.8)& 7&(33.3)& 3&(75.0)& 72&(72.0)& 137&(100)&
Treatment&& && && && && && &&
Transsphenoidal&surgery& 47&(100)& 26&(100)& 21&(100)& 3&(75)& 99&(99)& 137&(100)&
Reoperation& 3&(6.4)& 0&(0.0)& 2&(9.5)& 1&(25)& 6&(6.0)& 25&(18)&
Stereotactic&radiotherapy& 5&(11)& 0&(0.0)& 1&(4.8)& 2&(50)& 8&(8.0)& 27&(20)&
Suppressive&medication& 16&(34)& 16&(62)& 5&(24)& 0&(0)& 37&(37)& N/A&
Treatment&outcome&at&survey& && && && && && &&
Hormonal&remission***& 42&(89)& 22&(88)& 20&(95)& 4&(100)& 90&(91)& N/A&
Hypopituitarism****& 21&(45)& 7&(27)& 10&(48)& 2&(50)& 43&(44)& 86&(62)&
Mean&number&of&comorbidities**& 1.1&(±&0.8)& 0.68&(±&0.8)& 1.2&(±&0.8)& 0.25&(±&0.5)& 1&(±&0.83)& 1.3&(±&1.17)&
Data&is&presented&as&mean&±&SD&or&as&number&(percentage)&
*&including&combined&secretion&of&growth&hormone&and&prolactin&(n=2)& &
**&at&the&time&of&survey& &
***&at&last&followHup&(data&missing&n=1)&
****&hormonal&replacement&therapy&of&any&pituitary&axis&
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Within all subgroups (based on hormonal activity), the mean 15D score did 
not differ statistically between patients and the control population. However, 
patients with Cushing’s disease scored worse on two dimensions (vitality and 
sexual activity) than the control population. The 15D dimension profiles of 
patients with acromegaly and Cushing’s disease are presented in Figures 2b 
and 2c, respectively. 
The 15D dimension profiles of the NFPA cohort and the control population 
(n=4967), standardized for age and gender, are presented in Figure 2d. The 
mean 15D scores were 0.885 ±0.114 versus 0.903 ±0.093. The difference 
(0.018) is just greater than 0.015 and consequently regarded as clinically 
important, although not statistically significant (p=0.065). 
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Figure 2 a,b,c,d. The 15D profiles of different adenoma cohorts compared to the 
control population. 
2.3. Independent predictors of 15D score 
Impacts of various factors on the mean 15D score (marginal effects (B) in the 
Tobit model) are presented in Tables 11a and 11b for the FPA and NFPA 
cohorts, respectively. 
In FPA patients compared with acromegalic patients and standardized for 
all other independent variables, higher age, higher number of comorbidities, 
Cushing’s disease, and higher thyroxine replacement dose were independent 
predictors of impaired overall HRQoL. Radiotherapy or suppressive 
medication had no impact on mean 15D score. 
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In NFPA patients, age, BMI, comorbidities, reoperation, and thyroxine 
substitution were all independent predictors of impaired mean 15D score. 
Hydrocortisone and testosterone substitution (males only) were positive 
predictors of mean 15D score.  
NFPA patients with and without hydrocortisone substitution demonstrated no 
differences in single 15D dimension scores.  Males receiving testosterone 
replacement therapy scored higher on numerous single dimensions, including 
moving, breathing, excretion, mental function, and usual activities, than those 
not receiving testosterone replacement therapy. 
 
 
Table&11&a."&The&independent&impact&(the&Tobit&model)&of&various&
factors&on&the&15D&score&of&patients&with&FPAs.&
&& B& p@value&
Age&(years)& #0.0023" 0.0008"
Gender&(1=male,&0=female)& @0.0008& 0.9637&
Number&of&comorbidities& #0.0303" 0.0091"
Tumor&size&(1=macro,&0=micro)& @0.0415& 0.0514&
Follow@up&time&(years)& 0.0029& 0.2988&
Prolactinoma&(1=yes,&0=no)& @0.0042& 0.8438&
Cushing's&disease&(1=yes,&0=no)& #0.0488" 0.0341"
Hormonal&remission*&(1=yes,&0=no)& 0.0275& 0.3472&
Radiotherapy&(1=yes,&0=no)& 0.0114& 0.7002&
Suppressive&medication**&(1=yes,&0=no)& 0.0018& 0.9262&
Cortisone&replacement&(1=yes,&0=no)& @0.0002& 0.9942&
Growth&hormone&replacement&(1=yes,&0=no)& @0.0377& 0.4248&
Testosterone&replacement&(1=yes,&0=no)& 0.0404& 0.1884&
Thyroxine&dose&(µg/day)& #0.0005" 0.0024"
bold&indicates&statistical&significance&
*&at&last&follow@up&
**&at&the&time&of&the&survey&
 
 
Table&11&b.&Tobit,model&of&independent&factors&influencing&the&15D&score&of&
patients&with&NFPAs.&
! B& p,value&
Age! "0.0015! 0.0228!
Gender&(1=male,&0=female)& ,0.0381& 0.0562&
BMI& "0.0046! 0.0197!
Living&alone&(1=yes,&0=no)& ,0.0351& 0.0512&
Academic&education&(1=yes,&0=no)& 0.0128! 0.5102!
Diabetes&(1=yes,&0=no)& 0.0617! 0.0245!
Coronary&disease&(1=yes,&0=no)& ,0.0271! 0.2316!
Depression&(1=yes,&0=no)& "0.0852! 0.0004!
Cortisone&substitution&(1=yes,&0=no)& 0.0359! 0.0481!
Testosterone&substitution&(1=yes,&0=no)& 0.0880& <0.0005&
Thyroxine&substitution&(1=yes,&0=no)& "0.0583! 0.0018!
Operative&technique&(1=endoscopic,&0=microscopic)& 0.0164& 0.3593&
Reoperation&(1=yes,&0=no)& "0.0467& 0.0213&
Radiotherapy&(1=yes,&0=no)& 0.0200! 0.3604!
Normal&visual&function&(1=yes,&0=no)& 0.0098& 0.5507&
bold&indicates&statistical&significance&
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F. Discussion 
1. Transition from microscopic to endoscopic 
transsphenoidal surgery 
The first part of this study describes our single-center experience of the 
technical modification in transsphenoidal surgery for NFPAs in which we 
compared the outcomes before and after the transition in the operative 
technique. 
The endoscopic endonasal skull base operations can be divided into five levels 
(I-V) according to the degree of technical difficulty and the demand of surgical 
skills [98]. Pituitary operations correspond to level II and represent the first 
and perhaps the longest step in the progressive gain of experience needed to 
advance to the next level. Despite our limited foregoing endoscopic 
experience, the initial results of the endoscopic technique were comparable to 
those achieved with the microscopic technique. Moreover, there was a trend 
towards a higher rate of gross total resection in the Endoscopic group. The 
preceding 30-year institutional experience in transsphenoidal surgery at 
Helsinki University Hospital probably provided a strong basis for upgrading 
the technique, allowing quick adaptation to differences in surgical access and 
depth perception. 
Introducing a novel operative technique puts a surgeon at the bottom of a 
new learning curve [98, 201]. In this study, the multivariate analysis suggested 
that the tumor size (p<0.0005) was the strongest factor for longer mean 
operative time, and that the endoscopic technique was another independent 
factor (p=0.03) associated with a longer mean operative time. In earlier 
publications, endoscopic technique was associated with shorter operation 
times. However, preoperative tumor size or type was not included in their 
analyses [11, 137, 202, 203]. 
The midline structures, below the level of the diaphragm, are well 
visualized with both microscopic and endoscopic techniques.  However, 
suprasellar and lateral cavernous sinus compartments are usually “in a blind 
spot” of the microscopic view, while the endoscope provides an outstanding 
panoramic view, a view that can be further improved with angled optics. 
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According to this study, the gross total tumor removal was negatively 
influenced by larger preoperative tumor size and higher Knosp grade, but not 
by the surgical technique. The invasive nature of the pituitary adenoma seems 
to be the strongest factor impairing the surgical result in terms of total removal 
[9, 123]. Gross total removal was achieved more frequently in the Endoscopic 
group than in the Microscopic group (56% vs. 45%), in agreement with pre-
existing data (complete resection rates 36-83%) [68, 138, 204, 205]. This trend 
was observed also in the mean extent of resection (86% vs. 82%). In addition, 
we found that higher Knosp grade did not impair the quality of resection in the 
Endoscopic group. Overall, our results suggest a tendency towards improved 
quality of tumor removal in the Endoscopic group. 
Although the early reports of the endoscopic technique revealed a high 
incidence of CSF leakage (up to 10%), this complication rate decreased after 
introduction of correct methods for repair of the sellar floor [9, 90, 98, 125]. 
More recently, microscopic and endoscopic approaches have generally ranked 
equally regarding postoperative CSF leakage [10, 11, 125, 137]. In our series, 
we found no difference in postoperative CSF leakage between the two groups 
(3.5% vs. 2.4%), indicating that low rates of CSF leakage can be maintained 
even in early series of the endoscopic technique. 
There were two carotid artery injuries in the present series. Both occurred 
in the Microscopic group (1.4%). The frequent use of micro-Doppler for 
localizing the carotid arteries exclusively in the Endoscopic group may explain 
the difference. In a recent meta-analysis by Ammirati et al. [10] that compared 
short-term complications between the techniques, the only significant 
difference was a 3-fold risk of vascular complications with the endoscopic 
technique (1.6% vs. 0.5%). The authors suggested that this could be due to a 
more extensive sphenoid exposure of the carotid optic recess or to the lack of 
three-dimensional depth perception during suprasellar dissection. Our series 
does not support this conclusion since our vascular complications were the 
result of midline disorientation due to aberrant anatomy. 
We found that the need for hormonal substitution was equally distributed 
between the groups over time. The effect of surgery on overall pituitary 
function (assessed 3 months postoperatively) was slightly adverse in the 
Microscopic group (7% improved, 13% worse) and neutral in the Endoscopic 
group (9% improved, 9% worse). The proportion of hypopituitary patients 
(any one hormonal axis affected) increased after surgery from 59% to 65% 
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within the Microscopic group and from 56% to 61% within the Endoscopic 
group. The existing data on the effect of transsphenoidal surgery on pituitary 
function are not uniform. Some report a neutral effect similar to our series [9, 
132], but others [123, 138] describe overall improvement between 33% and 
72% and worsening between 1.5% and 7.5% of the separate pituitary axes. 
The discrepancies can be explained by the application of diverse endocrine 
tests (or no tests at all), by various criteria for the diagnosis of hypopituitarism, 
or by different surgical skills/technique. 
Transient postoperative DI, requiring at least one dose of desmopressin, was 
detected in 7.6% and 4.9% of microscopic and endoscopic cases, respectively. 
This corresponds well to the figures reported earlier for both techniques [10, 
123, 125]. 
At the end of follow-up (mean 68 months for microscopic cases and 22 
months for endoscopic cases), the need for replacement therapy had further 
increased in both groups. At this later stage, hypopituitarism is the result of the 
combined treatments (radiotherapy, repeat surgeries). Especially radiotherapy 
is known to have a harmful effect on pituitary function over time [72, 129]. 
In this study, the ophthalmological outcome was very good in both groups; 
90% of previously impaired visual fields and acuity either normalized or 
improved. Our finding is in line with earlier reports [9, 86, 123, 125] and 
supports the conclusion that the optic chiasm can be successfully 
decompressed with either of the transsphenoidal techniques. 
A recent retrospective and uncontrolled study of untreated NFPAs (n=66) 
indicated tumor progression in 58% of patients during a mean follow-up 
period of 4.3 years [206]. The overall median annual growth rate was 0.8 
mm/year (range 0.1-7.7 mm/year). Surgical series of treated NFPAs report 
progression of residual tumor in 8-70% (mean 43%) of cases during a 5-year 
postoperative follow-up [64]. We found tumor progression in 33% of our 
NFPA cohort (both groups combined) during a mean follow-up of 4.8 years. 
Due to different follow-up times between the Microscopic and Endoscopic 
groups (mean 5.7 vs. 1.8 years), no statistical comparisons were performed 
regarding medium- to long-term tumor control or pituitary function. Taken 
together, this data suggests that some NFPAs (naïve or residual), especially in 
elderly patients without tumor compression of the optic chiasm, may be 
managed conservatively with monitoring of pituitary function and serial 
neuro-ophthalmological and MRI studies. On the other hand, many NFPAs 
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tend to progress, which favors aggressive management with either gross total 
surgical removal or supplemented with STR. 
Outcomes after microscopic and endoscopic transsphenoidal pituitary 
surgery have been described in numerous publications. Yet, to date, there is no 
proof of the superiority of one technique over the other, with good results 
achieved with both techniques [71, 97, 123, 125, 138, 204, 207, 208]. 
However, several factors distinguish the microscopic from the endoscopic 
technique, and many of them are difficult (or impossible) to measure using 
scientific or statistical methods. From the surgeon’s (and the patient’s) point of 
view, the endoscopic technique can be preferred for numerous reasons. The 
anterior nasal structures may be better preserved. Since the approach is guided 
by anatomic structures, the need for fluoroscopy or neuronavigation is 
infrequent. The visual field and quality is superior to the microscopic view, 
enabling the technique to be utilized on more extensive tumors of the sellar 
region. Introducing instruments via both nostrils allows more precise 
microsurgical dissection as there is a wider and more comfortable range of 
movements than with a single tubular microscopic access through the nasal 
speculum. Furthermore, the assistants, students, and the entire surgical team 
can see and follow the surgical procedure through the same high-quality 
endoscopic videostream. 
2. Health-related quality of life (15D) after 
transsphenoidal surgery for pituitary adenoma 
The second part of our study compared the HRQoL of patients operated on for 
a pituitary adenoma with that of the general population. In addition, we 
estimated the independent factors affecting the overall HRQoL in our patients. 
Most existing data suggests that HRQoL is impaired after treatment of both 
FPA [170, 174, 175, 183, 184, 209] and NFPA [188, 189, 210, 211]. In this 
study we showed that the current treatment options allow normal or near-
normal HRQoL to be achieved in patients with FPAs and NFPAs after 
transsphenoidal surgery as a primary treatment. 
The 15D. We chose to measure the HRQoL with the 15D questionnaire, 
which is a generic instrument [212], unlike the AcroQoL and other disease-
specific questionnaires [165, 187].  The major advantage of the 15D is that it 
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allows us to compare our results with those of large, age- and gender-adjusted 
samples of the Finnish general population, recently compiled from the Finnish 
Health 2011 Survey [213]. In addition, the use of the 15D enabled indirect 
comparisons with the previous studies demonstrating impaired HRQoL in 
Finnish patients with acromegaly [214] and different pituitary adenoma 
subgroups [172]. 
Overall HRQoL. Our observation that the overall HRQoL of FPA patients 
after several years (mean 7.4 years) is similar to that of the general population 
is probably the result of two main factors: high remission rates (overall 91%) 
and optimal/physiological replacement therapy for hypopituitarism. Despite 
using strict remission criteria [39], high remission rates were anticipated in the 
acromegalic group (89%), and even higher rates in patients treated for 
Cushing’s disease (95%). However, patients with hormonally active disease 
(n=10) had HRQoL scores similar to patients in remission. This may seem 
conflicting, but this small subgroup of patients with active disease was 
significantly younger than those in remission, and younger age was a strong 
positive predictor of HRQoL in the multivariate analysis. 
In concordance with FPA patients, the overall HRQoL of our NFPA 
patients could be regarded as near-normal compared with that of the general 
population.  The difference in total 15D scores exceeded 0.015, which is 
considered the smallest clinically relevant difference [215], although the 
difference was not statistically significant (p=0.065).  Our findings are in line 
with another recent series, suggesting that it is possible to achieve near-normal 
HRQoL in surgically treated NFPA patients under regular follow-up and care 
in specialized pituitary centers [190]. 
Comorbidities. Our data clearly indicate that age and comorbidities are 
independent predictors of impaired overall HRQoL in PA patients. Over two-
thirds of our FPA and NFPA patients had at least one comorbidity and one-
third had two or more. The negative impact of various comorbidities on the 
overall HRQoL has been previously demonstrated [216]. Especially 
depression has a strong adverse effect on overall HRQoL and on mental 
components of functioning [217]. Similarly, several studies have demonstrated 
that the overall HRQoL in PA patients deteriorates with age [169, 188, 190, 
191]. 
An association between BMI and impaired 15D score was apparent in 
multivariate (p=0.020) analysis in our NFPA patients. The mean BMI of this 
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cohort was 26.9, which is close to the national average [218]. The correlation 
between impaired HRQoL and obesity is likewise well acknowledged [219, 
220]. 
Hypopituitarism and replacement therapy. Some [169, 188, 221], but not 
all [190, 194], previous studies have found hypopituitarism to be associated 
with impaired HRQoL. Hypopituitarism required (any) treatment in 62% of 
our NFPA patients, compared with the greater proportions of 73%, 87% and 
93% in previously published Danish [191], British [194], and Dutch [188] 
studies, respectively. The need for (any) replacement therapy was lower in our 
FPA patients than in our NFPA patients (44% vs. 62%), corresponding well to 
the literature reporting marked variation (range 27-52%) in (any) 
hypopituitarism in FPA patients [169, 174, 183, 184, 214]. This variation and 
the different treatment protocols and definitions for hypopituitarism likely 
explain the somewhat conflicting effects of hypopituitarism on overall 
HRQoL. 
In our patients (both FPA and NFPA), the overall HRQoL was 
independently impaired by thyroxine replacement. This may reflect clinicians 
aiming to alleviate nonspecific symptoms, such as discomfort and fatigue, 
with thyroxine when free T4 concentrations are in the low normal range. The 
follow-up protocol of the present cohort included yearly evaluation of 
hormonal replacement therapy and dose adjustments when needed. We also 
detected a positive and independent impact of hydrocortisone replacement 
therapy on overall HRQoL in NFPA patients. Concurrently, the mean 15D 
scores were equivalent in NFPA patients receiving (30%) and not receiving 
(70%) hydrocortisone. The mean hydrocortisone replacement dosing used was 
rather low, 14 mg (range 5-25 mg). This positive association probably reflects 
optimal dosing in this study, as both excessively low and excessively high 
hydrocortisone replacement dosages may impair well-being. A similar 
correlation of overall HRQoL with hydrocortisone replacement was not 
detected in FPA patients. This may be due to the smaller number of FPA 
patients receiving replacement therapy, as compared with NFPA patients, or 
the effect of optimal dosing of hydrocortisone (mean 15 mg, range 5–30 mg) 
in FPA patients. 
Males (NFPA) receiving testosterone replacement (40%) had significantly 
higher mean 15D score relative to NFPA patients not receiving testosterone 
replacement. This significant effect was seen in the following single 
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dimensions: moving, breathing, excretion, mental function, and usual activities 
(all p < 0.05). However, we did not detect a similar effect in male FPA 
patients, possibly due to the smaller proportion (29% vs. 40%) of patients 
receiving testosterone replacement therapy and their younger age (mean 56 vs. 
65 years) compared with their NFPA counterparts. Parallel to our results, 
Capatina et al. reported that males (NFPA cohort) with non-replaced 
hypogonadism scored significantly worse on several dimensions of daily 
living than males getting substitution for hypogonadism [190]. Others have not 
studied this aspect in NFPA patients in detail [188, 191]. 
Sexual activity. Our finding that sexual activity is impaired in PA patients 
compared with controls is interesting; limited data regarding this function after 
treatment of PA exist. Most authors [162, 169, 188, 191] have used the SF-36 
questionnaire, which does not assess sexual activity. Capatina et al. [190] used 
the NHP (along with the SF-36) questionnaire, which did include valuation of 
sex life (NHP second part). However, they did not find significant impairment 
in their NFPA study cohort (38% of male and 20% of female patients 
reporting sexual problems), but their control group was historical [222]. 
Previously, impairment of sexual function has been reported in only three 
studies: in acromegalic patients [214, 223] and in a small number of patients 
treated for prolactinoma [172]. The 15D profiles of our FPA subgroups, 
however, suggested impaired sexual activity in patients with Cushing’s disease 
(p=0.047), but not with acromegaly (p=0.058) or prolactinoma. In a sub-
analysis of our patients, impaired sexual activity seemed to be related to male 
gender and number of comorbidities in both FPA and NFPA patients. In 
addition, we observed a significant association between hydrocortisone 
replacement therapy and impaired sexual activity in FPA patients, but 
somewhat discordantly, not in NFPA patients. It remains unclear whether this 
reflects a true correlation or is related to the effect mediated by Cushing’s 
disease in which up to 35% of patients were receiving hydrocortisone 
replacement at the time of survey. 
Adenomas subtypes. Several studies have shown the deleterious effect of 
Cushing’s disease on HRQoL and mental condition, even after biochemical 
cure [180, 183, 184]. Likewise, our data suggest an independent negative 
effect of Cushing’s disease on overall HRQoL. Yet, the mean 15D score of 
patients with Cushing’s disease was equivalent to that of healthy controls, 
indicating that near-normal overall HRQoL can be achieved even in Cushing’s 
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disease. Since this subgroup was small, the results of our study must be 
interpreted with caution. The long-term hormonal remission in most Cushing’s 
patients best explains the exceptionally good overall HRQoL in this series. 
In 2008, a Dutch report on a large number (n=403) of diverse adenomas, 
using the SF-36, suggested all subscales of HRQoL to be most impaired in 
acromegaly, followed by Cushing’s disease, compared with prolactinoma 
patients and NFPA patients [169]. Importantly, however, these authors did not 
distinguish the effect of comorbidities on HRQoL from the impact of the 
disease itself. Furthermore, their control population (n = 440) was much 
smaller (than in our study), and the absolute HRQoL scores could only be 
compared at the whole study group (all adenomas combined) level. 
The largest study published on HRQoL in acromegalic patients using the 
15D reported significantly impaired HRQoL compared with a large age- and 
gender-adjusted control population. This study cohort included 231 patients 
diagnosed between 1980 and 1999, of whom 92% underwent surgery as 
primary treatment, but only 51% were in remission and 33% had been given 
adjuvant radiotherapy, which was administered as conventional two-field 
radiotherapy in the majority of cases. The present contemporary series of 
acromegalic patients had all been operated on transsphenoidally, 89% were in 
remission, and 11% had been given modern fractionated stereotactic 
radiotherapy, but none conventional radiotherapy. 
Two longitudinal studies demonstrated positive effects of improved 
hormonal control in acromegaly on overall HRQoL using the AcroQoL 
questionnaire during a 6-month follow-up [165, 224]. Conversely, another 
longitudinal study (4-year follow-up) using both the SF-36 and the AcroQoL 
reported progressive impairment of HRQoL in biochemically cured 
acromegalic patients, with previous radiotherapy being the predominant 
independent impairing factor [225]. These authors did not, however, compare 
the results with those of age- and gender-matched controls, nor did they 
consider the possible negative effect of other comorbidities on HRQoL in 
acromegaly. Likewise, the effect of SSA treatment on HRQoL remains 
unsettled, with opposing effects reported [179, 226]. Since only a small 
number (n=11) of our acromegalic patients were on SSA treatment at the time 
of survey, our study did not allow for definite conclusions regarding the effect 
of SSA treatment on HRQoL. 
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Previous reports on HRQoL of prolactinoma patients, the majority of 
whom were treated with dopamine agonists alone, are conflicting [169, 171]. 
Our data, albeit based on a small number of patients (n=26), indicate that 
HRQoL is not impaired in prolactinoma patients treated with transsphenoidal 
surgery a mean of 7.6 years earlier, 62% of whom had received adjuvant 
therapy, with a remission rate of 88%. 
A Finnish study assessing HRQoL (and using 15D questionnaire) in 
patients with diverse pituitary adenomas suggested impaired HRQoL in 
patients with Cushing’s disease, prolactinoma, or acromegaly on SSA 
treatment, but not in NFPA patients [172]. This author’s conclusions are 
limited by the small number of patients in subgroups (45 FPA and 53 NFPA 
patients), the older series (surgery performed in 1992-2004), and the outdated 
remission criteria for the 22 acromegalic patients. In addition, 12% of their 
patients (n =12) had undergone craniotomy, compared with the almost 
exclusively transsphenoidally operated patients (only one craniotomy) in the 
present FPA cohort. 
Visual function. Decompression of the optic nerve(s) and chiasm is a major 
indication for surgery in patients with NFPA. Available data regarding the 
effect of visual function on HRQoL after pituitary surgery are limited and in 
part conflicting. Cross-sectional studies of NFPA patients have either 
suggested a negative effect of post-operative residual visual deficit (vs. no 
deficit) on HRQoL score (interests and hobbies subscale of the NHP),[190] or 
observed no effect of residual visual deficit on any HRQoL scores (SF-36, 
NHP, MFI). Our NFPA cohort had a significantly impaired single dimension 
of sight relative to controls, although the Tobit model did not suggest an 
independent impact of visual function on overall HRQoL. Similarly, in a study 
comparing cataract patients with controls, no differences emerged in the mean 
15D score, but the single dimension of seeing was significantly impaired in the 
patient group [227]. 
Re-operation. We found an independent negative effect of re-operation on 
overall HRQoL. Some of our NFPA patients (18%) had to undergo re-
operation, which required a transcranial approach in 28% of cases instead of 
the transsphenoidal route used in 72%. Due to invasive growth, the tumor 
remnant could be totally excised in only two cases (8%). In addition, 14 (56%) 
of the re-operated NFPA patients were given adjuvant stereotactic 
radiotherapy as a consequence of tumor remnant progression. This group of re-
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operated NFPA patients was thus characterized by persistent disease, and 
some of them underwent craniotomy followed by radiotherapy. This strenuous 
treatment protocol and most patients being left with residual tumors 
presumably explain why re-operation impaired their overall HRQoL. Others 
have similarly reported impaired HRQoL after craniotomy or re-operation 
[190, 191]. In our FPA patients, re-operation was rare (n=6), and its effect on 
HRQoL was not investigated. 
Surgical technique. The mean 15D score in our NFPA patients was not 
altered by the transsphenoidal technique (microscopic vs. endoscopic). This 
was expected since we (first part of this study) and others [10] have 
demonstrated that short-term outcome is similar with both techniques, and the 
survey took place a mean of 7.4 years after the surgery. 
Radiotherapy. Stereotactic radiotherapy was administered to 8% of our 
FPA patients and 20% of NFPA patients. The Tobit model did not suggest any 
impairing effect on HRQoL in either group. Modern methods of delivering 
ionized radiation for tumor control may be safer than conventional two-field 
radiotherapy, and a recent large study with 42% of a NFPA cohort having 
undergone radiotherapy suggested, in line with our results, no effect on 
HRQoL [190]. 
3. Limitations of the study 
The first part of our study is limited by the retrospective design, the absence of 
contemporary controls, and the disproportion of number of patients and mean 
follow-up times between the groups. Especially the relatively small number of 
endoscopic cases reduces the power of the study to detect differences between 
the groups. Although no difference between the surgeons emerged in operative 
time or extent of resection, we cannot exclude the impact of surgeon-specific 
differences. Due to a continuous learning curve in all surgical procedures, the 
primary surgeons might have built up surgical knowledge and skills in 
pituitary surgery during the 11-year course of the study. This could have 
prejudiced the results in favor of the Endoscopic group. 
The main limitation of the second part of our study is the relatively small 
number of patients in the FPA subgroups. No recruitment bias occurred, 
however, as our cohort represents a consecutive surgical series in a single 
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institution covering a population of nearly 2 million people. Moreover, during 
an 11-year period no patients were lost to follow-up, and the response rate was 
as high as 78% in the FPA cohort. Due to the cross-sectional study design, we 
cannot comment on a possible change in HRQoL score during the course of 
pituitary disease and its treatment. 
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G. Conclusions and future prospects 
With this study, we show a smooth transition from microscopic to endoscopic 
transsphenoidal surgery for pituitary adenomas, as we could maintain the 
previous level of outcome, with a trend towards improved quality of resection. 
Our initial endoscopic results serve as an encouraging example for those 
pituitary centers and surgeons considering an introduction of the endoscopic 
technique. 
Findings in this study also suggest that current multimodal treatment 
protocols with optimized hormonal replacement therapies allow normal or 
near-normal overall HRQoL in patients with all types of pituitary adenomas. 
Older age and cumulative comorbidities are often the major determinants of 
HRQoL in patients treated for pituitary adenomas. 
The quest for an optimal surgical approach and technique for removing 
pituitary adenomas continues. Improved methods and applications of 
intraoperative viewing with ultra-high definition and 3D endoscopic 
videostreaming will help subspecialized pituitary surgeons in their attempts to 
remove tumors. A randomized study would be the gold standard for proving 
the superiority of a novel method. However, the endoscopic technique is 
already such an established method that we are unlikely to see its 
randomization against the microscopic approach. Instead, prospective data 
collection (electronic databases) will increase, and the outcomes in terms of 
hormonal function, tumor control, and HRQoL will be constantly monitored to 
evaluate treatment (cost)effectiveness. Novel targeted medication, especially 
for hormonally active adenomas, is being developed, and it remains to be seen 
how long surgical treatment will hold the status of principal treatment method 
for acromegaly or Cushing’s disease. 
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Appendices 
Appendix 1 
QUALITY OF LIFE QUESTIONNAIRE 
(15D©)/Harri Sintonen 
 
Please read all of the alternative responses to each question before marking with an x the 
alternative best describing your present health status. Answer all 15 questions in this 
manner, providing only one response for each question. 
 
QUESTION 1. MOBILITY 
1() I am able to walk normally (without difficulty) indoors, outdoors, and on stairs. 
2() I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight 
difficulties. 
3() I am able to walk without help indoors (with or without an appliance), but outdoors 
and/or on stairs only with considerable difficulty or with help from others. 
4() I am able to walk indoors only with help from others. 
5() I am completely bedridden and unable to move about. 
 
QUESTION 2. VISION 
1() I see normally, i.e. I can read newspapers and TV text without difficulty (with or 
without glasses). 
2() I can read papers and/or TV text with slight difficulty (with or without glasses). 
3() I can read papers and/or TV text with considerable difficulty (with or without glasses). 
4() I cannot read papers or TV text with glasses or without, but I can see enough to walk 
about without guidance. 
5() I cannot see enough to walk about without a guide, i.e. I am almost or completely 
blind. 
 
QUESTION 3. HEARING 
1() I can hear normally, i.e. normal speech (with or without a hearing aid). 
2() I hear normal speech with a little difficulty. 
3() I hear normal speech with considerable difficulty; in conversation I need voices to be 
louder than normal. 
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4() I hear even loud voices poorly; I am almost deaf. 
5() I am completely deaf. 
 
QUESTION 4. BREATHING 
1() I am able to breathe normally, i.e. with no shortness of breath or other breathing 
difficulty. 
2() I have shortness of breath during heavy work or sports, or when walking briskly on 
flat ground or slightly uphill. 
3() I have shortness of breath when walking on flat ground at the same speed as others my 
age. 
4() I get shortness of breath even after light activity, e.g. washing or dressing myself. 
5() I have breathing difficulties almost all the time, even when resting. 
 
QUESTION 5. SLEEPING 
1() I am able to sleep normally, i.e. I have no problems with sleeping. 
2() I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes 
waking at night. 
3() I have moderate problems with sleeping, e.g. disturbed sleep, or the feeling that I have 
not slept enough. 
4() I have great problems with sleeping, e.g. having to use sleeping pills often or 
routinely, or usually waking at night and/or too early in the morning. 
5() I suffer from severe sleeplessness, e.g. sleep is almost impossible even with use of 
sleeping pills, or I stay awake most of the night. 
 
QUESTION 6. EATING 
1() I am able to eat normally, i.e. with no help from others. 
2() I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with 
special appliances). 
3() I need some help from another person with eating. 
4() I am unable to eat by myself at all so I must be fed by another person. 
5() I am unable to eat at all, so I am fed either by tube or intravenously. 
 
QUESTION 7. SPEECH 
1() I am able to speak normally, i.e. clearly, audibly, and fluently. 
2() I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or 
changes of pitch. 
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3() I can make myself understood, but my speech is disjointed, faltering, stuttering, or 
stammering. 
4() Most people have great difficulty understanding my speech. 
5() I can only make myself understood by gestures. 
 
QUESTION 8. EXCRETION 
1() My bladder and bowel work normally and without problems. 
2() I have slight problems with my bladder and/or bowel function, e.g. difficulties with 
urination, or loose or hard stools. 
3() I have marked problems with bladder and/or bowel function, e.g. occasional 
'accidents', or severe constipation or diarrhea. 
4() I have serious problems with my bladder and/or bowel function, e.g. routine 
'accidents', or need catheterization or enemas. 
5() I have no control over my bladder and/or bowel function. 
 
QUESTION 9. USUAL ACTIVITIES 
1() I am able to perform my usual activities (e.g. employment, studying, housework, free-
time activities) without difficulty. 
2() I am able to perform my usual activities slightly less effectively or with minor 
difficulty. 
3() I am able to perform my usual activities much less effectively, with considerable 
difficulty, or incompletely. 
4() I can only manage a small proportion of my previous usual activities. 
5() I am unable to manage any of my previous usual activities. 
 
QUESTION 10. MENTAL FUNCTION 
1() I am able to think clearly and logically, and my memory functions well. 
2() I have slight difficulties in thinking clearly and logically, or my memory sometimes 
fails me. 
3() I have marked difficulties in thinking clearly and logically, or my memory is 
somewhat impaired. 
4() I have great difficulties in thinking clearly and logically, or my memory is seriously 
impaired. 
5() I am permanently confused and disoriented in place and time. 
 
QUESTION 11. DISCOMFORT AND SYMPTOMS 
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1() I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc. 
2() I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc. 
3() I have moderate physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc. 
4() I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching, etc. 
5() I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching, 
etc. 
 
QUESTION 12. DEPRESSION 
1() I do not feel at all sad, melancholic, or depressed. 
2() I feel slightly sad, melancholic, or depressed. 
3() I feel moderately sad, melancholic, or depressed. 
4() I feel very sad, melancholic, or depressed. 
5() I feel extremely sad, melancholic, or depressed. 
 
QUESTION 13. DISTRESS 
1() I do not feel at all anxious, stressed, or nervous. 
2() I feel slightly anxious, stressed, or nervous. 
3() I feel moderately anxious, stressed, or nervous. 
4() I feel very anxious, stressed, or nervous. 
5() I feel extremely anxious, stressed, or nervous. 
 
QUESTION 14. VITALITY 
1() I feel healthy and energetic. 
2() I feel slightly weary, tired, or feeble. 
3() I feel moderately weary, tired, or feeble. 
4() I feel very weary, tired, or feeble, almost exhausted. 
5() I feel extremely weary, tired, or feeble, totally exhausted. 
 
QUESTION 15. SEXUAL ACTIVITY 
1() My state of health has no adverse effect on my sexual activity. 
2() My state of health has a slight effect on my sexual activity. 
3() My state of health has a considerable effect on my sexual activity. 
4() My state of health makes sexual activity almost impossible. 
5() My state of health makes sexual activity impossible. 
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Appendix 2 
TERVEYTEEN LIITTYVÄN ELÄMÄNLAADUN KYSELYLOMAKE 
(15D©)/Harri Sintonen (in Finnish) 
 
Ohje: Lukekaa ensin läpi huolellisesti kunkin kysymyksen kaikki vastausvaihtoehdot. 
Merkitkää sitten rasti (x) sen vaihtoehdon kohdalle, joka parhaiten kuvaa nykyistä 
terveydentilaanne. Menetelkää näin kaikkien kysymysten 1-15 kohdalla. Kustakin 
kysymyksestä rastitetaan siis yksi vaihtoehto. 
 
KYSYMYS 1. LIIKUNTAKYKY 
1 ( ) Pystyn kävelemään normaalisti (vaikeuksitta) sisällä, ulkona ja portaissa. 
2 ( ) Pystyn kävelemään vaikeuksitta sisällä, mutta ulkona ja/tai portaissa on pieniä 
vaikeuksia. 
3 ( ) Pystyn kävelemään ilman apua sisällä (apuvälinein tai ilman), mutta ulkona ja/tai 
portaissa melkoisin vaikeuksin tai toisen avustamana. 
4 ( ) Pystyn kävelemään sisälläkin vain toisen avustamana. 
5 ( ) Olen täysin liikuntakyvytön ja vuoteenoma. 
 
KYSYMYS 2. NÄKÖ 
1 ( ) Näen normaalisti eli näen lukea lehteä ja TV:n tekstejä vaikeuksitta (silmälaseilla tai 
ilman). 
2 ( ) Näen lukea lehteä ja/tai TV:n tekstejä pienin vaikeuksin (silmälaseilla tai ilman). 
3 ( ) Näen lukea lehteä ja/tai TV:n tekstejä huomattavin vaikeuksin (silmälaseilla tai 
ilman). 
4 ( ) En näe lukea lehteä enkä TV:n tekstejä ilman silmälaseja tai niiden kanssa, mutta 
näen kulkea ilman opasta. 
5 ( ) En näe kulkea oppaatta eli olen lähes tai täysin sokea. 
 
KYSYMYS 3. KUULO 
1 ( ) Kuulen normaalisti eli kuulen hyvin normaalia puheääntä (kuulokojeella tai ilman). 
2 ( ) Kuulen normaalia puheääntä pienin vaikeuksin. 
3 ( ) Minun on melko vaikea kuulla normaalia puheääntä, keskustelussa on käytettävä 
normaalia kovempaa puheääntä. 
4 ( ) Kuulen kovaakin puheääntä heikosti; olen melkein kuuro. 
5 ( ) Olen täysin kuuro. 
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KYSYMYS 4. HENGITYS 
1 ( ) Pystyn hengittämään normaalisti eli minulla ei ole hengenahdistusta eikä muita 
hengitysvaikeuksia. 
2 ( ) Minulla on hengenahdistusta raskaassa työssä tai urheillessa, reippaassa kävelyssä 
tasamaalla tai lievässä ylämäessä. 
3 ( ) Minulla on hengenahdistusta, kun kävelen tasamaalla samaa vauhtia kuin muut 
ikäiseni. 
4 ( ) Minulla on hengenahdistusta pienenkin rasituksen jälkeen, esim. peseytyessä tai 
pukeutuessa. 
5 ( ) Minulla on hengenahdistusta lähes koko ajan, myös levossa. 
 
KYSYMYS 5. NUKKUMINEN 
1 ( ) Nukun normaalisti eli minulla ei ole mitään ongelmia unen suhteen. 
2 ( ) Minulla on lieviä uniongelmia, esim. nukahtamisvaikeuksia tai satunnaista 
yöheräilyä. 
3 ( ) Minulla on melkoisia uniongelmia, esim. nukun levottomasti tai uni ei tunnu 
riittävältä. 
4 ( ) Minulla on suuria uniongelmia, esim. joudun käyttämään usein tai säännöllisesti 
unilääkettä, herään säännöllisesti yöllä ja/tai aamuisin liian varhain. 
5 ( ) Kärsin vaikeasta unettomuudesta, esim. unilääkkeiden runsaasta käytöstä huolimatta 
nukkuminen on lähes mahdotonta, valvon suurimman osan yöstä. 
 
KYSYMYS 6. SYÖMINEN 
1 ( ) Pystyn syömään normaalisti eli itse ilman mitään vaikeuksia. 
2 ( ) Pystyn syömään itse pienin vaikeuksin (esim. hitaasti, kömpelösti, vavisten tai 
erityisapuneuvoin). 
3 ( ) Tarvitsen hieman toisen apua syömisessä. 
4 ( ) En pysty syömään itse lainkaan, vaan minua pitää syöttää. 
5 ( ) En pysty syömään itse lainkaan, vaan minulle pitää antaa ravintoa letkun avulla tai 
suonensisäisesti. 
 
KYSYMYS 7. PUHUMINEN 
1 ( ) Pystyn puhumaan normaalisti eli selvästi, kuuluvasti ja sujuvasti. 
2 ( ) Puhuminen tuottaa minulle pieniä vaikeuksia, esim. sanoja on etsittävä tai ääni ei ole 
riittävän kuuluva tai se vaihtaa korkeutta. 
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3 ( ) Pystyn puhumaan ymmärrettävästi, mutta katkonaisesti, ääni vavisten, sammaltaen 
tai änkyttäen. 
4 ( ) Muilla on vaikeuksia ymmärtää puhettani. 
5 ( ) Pystyn ilmaisemaan itseäni vain elein. 
 
KYSYMYS 8. ERITYSTOIMINTA 
1 ( ) Virtsarakkoni ja suolistoni toimivat normaalisti ja ongelmitta. 
2 ( ) Virtsarakkoni ja/tai suolistoni toiminnassa on lieviä ongelmia, esim. minulla on 
virtsaamisvaikeuksia tai kova tai löysä vatsa. 
3 ( ) Virtsarakkoni ja/tai suolistoni toiminnassa on melkoisia ongelmia, esim. minulla on 
satunnaisia virtsanpidätysvaikeuksia tai vaikea ummetus tai ripuli. 
4 ( ) Virtsarakkoni ja/tai suolistoni toiminnassa on suuria ongelmia, esim. minulla on 
säännöllisesti "vahinkoja" tai peräruiskeiden tai katetroinnin tarvetta. 
5 ( ) En hallitse lainkaan virtsaamista ja/tai ulostamista. 
 
KYSYMYS 9. TAVANOMAISET TOIMINNOT 
1 ( ) Pystyn suoriutumaan normaalisti tavanomaisista toiminnoista (esim. ansiotyö, 
opiskelu, kotityö, vapaa-ajan toiminnot). 
2 ( ) Pystyn suoriutumaan tavanomaisista toiminnoista hieman alentuneella teholla tai 
pienin vaikeuksin. 
3 ( ) Pystyn suoriutumaan tavanomaisista toiminnoista huomattavasti alentuneella teholla 
tai huomattavin vaikeuksin tai vain osaksi. 
4 ( ) Pystyn suoriutumaan tavanomaisista toiminnoista vain pieneltä osin. 
5 ( ) En pysty suoriutumaan lainkaan tavanomaisista toiminnoista. 
 
KYSYMYS 10. HENKINEN TOIMINTA 
1 ( ) Pystyn ajattelemaan selkeästi ja johdonmukaisesti ja muistini toimii täysin 
moitteettomasti. 
2 ( ) Minulla on lieviä vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai muistini ei 
toimi täysin moitteettomasti. 
3 ( ) Minulla on melkoisia vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai minulla on 
jonkin verran muistinmenetystä. 
4 ( ) Minulla on suuria vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai minulla on 
huomattavaa muistinmenetystä. 
5 ( ) Olen koko ajan sekaisin ja vailla ajan tai paikan tajua. 
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KYSYMYS 11. VAIVAT JA OIREET 
1 ( ) Minulla ei ole mitään vaivoja tai oireita, esim. kipua, särkyä, pahoinvointia, kutinaa 
jne. 
2 ( ) Minulla on lieviä vaivoja tai oireita, esim. lievää kipua, särkyä, pahoinvointia, 
kutinaa jne. 
3 ( ) Minulla on melkoisia vaivoja tai oireita, esim. melkoista kipua, särkyä, 
pahoinvointia, kutinaa jne. 
4 ( ) Minulla on voimakkaita vaivoja tai oireita, esim. voimakasta kipua, särkyä, 
pahoinvointia, kutinaa jne. 
5 ( ) Minulla on sietämättömiä vaivoja ja oireita, esim. sietämätöntä kipua, särkyä, 
pahoinvointia, kutinaa jne. 
 
KYSYMYS 12. MASENTUNEISUUS 
1 ( ) En tunne itseäni lainkaan surulliseksi, alakuloiseksi tai masentuneeksi. 
2 ( ) Tunnen itseni hieman surulliseksi, alakuloiseksi tai masentuneeksi. 
3 ( ) Tunnen itseni melko surulliseksi, alakuloiseksi tai masentuneeksi. 
4 ( ) Tunnen itseni erittäin surulliseksi, alakuloiseksi tai masentuneeksi. 
5 ( ) Tunnen itseni äärimmäisen surulliseksi, alakuloiseksi tai masentuneeksi. 
 
KYSYMYS 13. AHDISTUNEISUUS 
1 ( ) En tunne itseäni lainkaan ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
2 ( ) Tunnen itseni hieman ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
3 ( ) Tunnen itseni melko ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
4 ( ) Tunnen itseni erittäin ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
5 ( ) Tunnen itseni äärimmäisen ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
 
KYSYMYS 14. ENERGISYYS 
1 ( ) Tunnen itseni terveeksi ja elinvoimaiseksi. 
2 ( ) Tunnen itseni hieman uupuneeksi, väsyneeksi tai voimattomaksi. 
3 ( ) Tunnen itseni melko uupuneeksi, väsyneeksi tai voimattomaksi. 
4 ( ) Tunnen itseni erittäin uupuneeksi, väsyneeksi tai voimattomaksi, lähes "loppuun 
palaneeksi". 
5 ( ) Tunnen itseni äärimmäisen uupuneeksi, väsyneeksi tai voimattomaksi, täysin 
"loppuun palaneeksi". 
 
KYSYMYS 15. SUKUPUOLIELÄMÄ 
 94 
1 ( ) Terveydentilani ei vaikeuta mitenkään sukupuolielämääni. 
2 ( ) Terveydentilani vaikeuttaa hieman sukupuolielämääni. 
3 ( ) Terveydentilani vaikeuttaa huomattavasti sukupuolielämääni. 
4 ( ) Terveydentilani tekee sukupuolielämäni lähes mahdottomaksi. 
5 ( ) Terveydentilani tekee sukupuolielämäni mahdottomaksi 
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Appendix 3 
ADDITIONAL QUESTIONNAIRE 
 
1) What is your marital status?  
unmarried _____ 
partner _____ 
married  _____ 
divorced or legally separated_____ 
widow _____ 
 
2) What is your education (highest degree)? 
elementary school  _____ 
vocational school _____ 
high school _____ 
institutional _____ 
college (e.g. polytechnic) _____ 
university _____ 
  
3) Have you other diseases ?   no   yes 
 
4) If yes, please specify? 
a) diabetes, type 1      no   yes     
b) diabetes, type 2     no   yes    
c) hypertension      no   yes 
d) coronary disease     no    yes 
e) depression      no    yes 
f) other, what 
___________________________________________________________________________ 
 
5) Current weight_________kg  
6) Height         ___________cm 
 
7) Current medication (all medicines and hormonal replacements, name, composition, dosing, 
timing) 
 
Name of drug, composition  Dose and time: 
(e.g.   Hydrocortisone 10 mg  1 pill at 8 AM, ½ pill at 4 PM)   
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
 
8) Where (which hospital) is your follow-up scheduled? 
______________________________________________(name of hospital and doctor) 
9) When was your last follow-up visit?_______________________(date) 
10) Date (filling this questionnaire)___________________ 
11) You may write additional comments on the reverse side of this questionnaire  
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Appendix 4 
KYSELYKAAVAKE (in Finnish) 
 
1) Mikä on siviilisäätynne?  
naimaton _____ 
avopuoliso _____ 
naimisissa  _____ 
eronnut tai asumuserossa _____ 
leski _____ 
 
2) Mikä on koulutuksenne (korkein suoritettu koulutus)? 
peruskoulu  _____ 
ammattikoulu _____ 
lukio _____ 
opistotasoinen koulutus _____ 
ammattikorkeakoulu _____ 
yliopisto/korkeakoulu _____ 
  
3) Onko Teillä todettu muita sairauksia ?   ei   kyllä 
 
4) Jos vastasitte edelliseen kysymykseen myöntävästi, niin mitä sairauksia? 
a) Tyypin 1 diabetes      ei   kyllä     
b) Tyypin 2  diabetes     ei   kyllä    
c) Verenpainetauti     ei   kyllä 
d) Sepelvaltimotauti     ei    kyllä 
e) Masennus      ei    kyllä 
f) muu sairaus, mikä 
___________________________________________________________________________ 
 
5) Nykypainoni_________kg  
6) Pituuteni   ___________cm 
 
7) Nykylääkitykseni (kaikki lääkkeet ja hormonivalmisteet, nimi, vahvuus, annostus, 
ajankohta) 
 
Lääkkeen nimi ja vahvuus  Annos ja ajankohta: 
(esim   Hydrocortison 10 mg  1 tabletti klo 8, ½ tablettia klo 16)   
___________________________________________________________________________
___________________________________________________________________________ 
 
8) Missä aivolisäkekasvaintanne seurataan tällä hetkellä? 
______________________________________________(hoitopaikan ja lääkärin nimi) 
9) Koska olitte viimeksi kontrollissa?_______________________(päivämäärä) 
10) Päivämäärä (jolloin täytitte lomakkeen)___________________ 
11) Mahdolliset muut huomatuksenne voitte kirjoittaa lomakkeen kääntöpuolelle  
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